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ABSTRACT 
Cancer accounts for nearly one-quarter of deaths in the United States, exceeded only by heart 
diseases.  In 2006, there were 559,888 cancer deaths in the US. Finding effective treatments for 
cancer is a major challenge among researchers.  In solid tumor, hypoxia increases the progres-
sion of malignancy and metastasis by promoting angiogenesis.  The transcription factor HIF-1 is 
responsible for the regulation of cellular processes, including glycolysis and angiogenesis.  Clin-
ical evidence has determined that expression of HIF-1 is strongly associated with poor patient 
prognosis.  Also, activation of HIF-1 contributes to malignant behavior and therapeutic resis-
tance.  In view of these observations, there is a need for anti-cancer treatments that addresses 
hypoxic related tumors.  HIF-1 presents a viable target for inhibition of tumor growth with small 
molecules.  Herein, we describe the design and synthesis of small molecules that inhibit the 
 
 
HIF-1 pathway, as well as mechanistic studies involved in the investigation of the mode of ac-
tion of these compounds. 
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1 INTRODUCTION 
Cancer accounts for nearly one-quarter of deaths in the United States, exceeded only by 
heart disease.1  Although there have been many new treatments, cancer still claims many lives. 
As a result, there is a need for new therapeutics that address this problem.  Hypoxia is charac-
terized by a reduction in the partial oxygen pressure in cells and/or tissue and is characteristic of 
solid tumors.  Tumor hypoxia has been shown to reduce the effectiveness of radiation and che-
motherapy.2, 3  According to Powis and Kilpatrick, oxygen can diffuse 100 –180 M from the end 
of the nearest capillary to the cells before it is used up completely.4  Consequently, in solid tu-
mors, when the existing vascular system is unable to supply the growing tumor with adequate 
amounts of oxygen, it results in hypoxia, low pH and a lack of sufficient nutrients5, 6   
Hypoxia Inducible Factor (HIF) is the primary transcription factor activated by hypoxia and is 
responsible for orchestrating a number of cellular responses (such as angiogenesis and glyco-
lysis) that help tumor cells adapt to hypoxic conditions.7  HIF-1 is a basic helix-loop-helix hete-
rodimeric transcription factor and is composed of two subunits: HIF-1 and the constitutively 
expressed HIF-1.    
The levels of HIF-1 are determined by intracellular oxygen concentration (Figure 1).  Un-
der normoxic conditions, HIF-1 is continually degraded by ubiquitination and proteosomal de-
gradation.  Degradation occurs when HIF-1 is hydroxylated at Pro 564 and Pro 402 located at 
its oxygen-dependent degradation domain (ODDD).  This process is facilitated by the prolyl hy-
droxylase enzyme that requires oxygen, iron and 2-oxoglutarate as the co-substrate to hydrox-
ylate the specific amino acid residues.8-10   After hydroxylation, HIF-1 binds to Von Hippel-
Lindau protein (pVHL) and becomes a part of the E3-ubiquitin lipase complex, such that, HIF-1 
is ubiquitinated and thereby marked for proteasomal degradation.11, 12   Oxygen is required for 
the function of the prolyl hydroxylase enzyme.  Therefore, under hypoxic conditions, HIF-1 is 
stabilized.  Once stabilized, HIF-1 accumulates and translocates to the nucleus where it inte-
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racts with HIF-1 to form the active transcription factor, HIF-1.11, 12  HIF-1 then activates a num-
ber of cellular genes by binding to the DNA sequence 5`-ACGTG-3`.  So far, more than 100 
genes have been identified that are activated by HIF.13, 14   The activated genes includes those 
for proteins that carry out anaerobic glycolysis, for erythropoietin (red blood cell production), and 
for vascular endothelial cell growth factor (VEGF).  VEGF is believed to be a powerful stimulus 
to new capillary formation, is a major driver of tumor angiogenesis and is the primary transcrip-
tion factor activated by hypoxia.15  The overexpression of HIF-1 is indicated in a number of 
human cancers16-18 and is associated with poor response to treatment and patient mortality.16, 19-
22  As a result, HIF-1 has been investigated for its potential as an anti-tumor therapeutic target 
with small molecules.23, 24 
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Figure 1.  Hypoxia-Inducible Factor (HIF) Pathway of Hypoxia Control 
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1.1  Effect of Hypoxia on Tumors 
  In order for cells to survive in a hypoxic environment, they adopt a number of mechan-
isms that trigger apoptotic resistance, angiogenesis, and glycolysis.  Cell proliferation and me-
tastasis is also promoted.   
Tumors are able to grow uncontrollably because the balance of cell growth versus cell 
death is disrupted.  Some of the antiapoptotic activity of cancer cells may be the result of hypox-
ic conditions.25  The adaptive mechanisms that cancer cells develop in response to hypoxia 
causes them to multiply faster than normal cells.3   The expression of various proteins in re-
sponse to hypoxia may have an effect on apoptosis activity.  For example, hypoxia can induce 
the production of anti-apoptosis protein IAP-2.26   Another protein, periostin, can significantly 
increase metastasis of colon cancer by preventing apoptosis.27  Also, ostrepontin (OPN) has 
been identified as a protein that plays an important role in tumor development.28, 29  OPN is 
thought to promote tumor development through Akt activation that enables cell survival under 
stress related conditions.30, 31  
As cancer cells proliferate and tumors increase in size, a larger blood supply is needed 
to provide adequate oxygen and nutrients. 29  Hypoxia can induce factors such as VEGF and 
angiogenin that promote angiogenesis.  VEGF has an especially important role in angiogenesis 
in tumors.32, 33  It is well established that hypoxic conditions will cause an increase in HIF-1 ac-
tivity, which in turn enhances VEGF levels leading to increased angiogenesis 34-36.   
There are two schools of thought on the role of hypoxia in inducing angiogenesis.  The 
first is known as the hypoxic crisis model,37 which suggests that hypoxia leads to angiogenesis.  
This model proposes that initial overexpression of angiopoietin 2 leads to hypoxia, which in turn 
causes upregulation of VEGF.   VEGF then promotes angiogenesis. The second model, the ac-
celeration model38 proposes that hypoxia is not responsible for promoting angiogenesis, but in-
stead, angiogenesis is initiated by VEGF-promoting oncogenes.  In essence, angiogenesis 
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leads to tumor cell proliferation.  The poorly formed blood vessels will promote hypoxia. Be-
cause of hypoxia, HIF-1 is upregulated. These two models may be at work in angiogenesis and 
proliferation of tumor cells. 
Hypoxia can also have an effect on glycolysis.  Under hypoxic conditions cancer cells 
tend to move their ATP production from aerobic to anaerobic via glycolysis.  Hypoxic cancer 
cells use glycolysis as a primary mechanism of ATP production, and HIFs are master regulators 
of glucose metabolism during hypoxia.3, 5, 39, 40  
Given the discussed roles of hypoxia in solid tumors and the fact that HIF-regulated 
genes are linked to cancer progression, inhibition of HIF activity may have therapeutic potential 
for cancer. 
1.2 HIF-1 inhibitors  
Several research groups have identified compounds that have been known to inhibit the 
HIF-1 pathway.  These compounds affect HIF-1 levels by directly inhibiting HIF-1 signaling or by 
indirectly inhibiting signal pathways that affect HIF-1 expression.  The mechanisms of action for 
HIF-1 inhibitors involve reduction in HIF1-  mRNA levels or protein levels, HIF-1 DNA-binding 
activity or HIF-1 mediated transactivation of target genes.   Compounds may also reduce protein 
levels by decreasing the rate of HIF-1 synthesis or by increasing the rate of HIF-1 degrada-
tion.   Several reviews have been published that describe HIF-1 inhibitors.24, 35, 41, 42 
Hsp90 inhibitors are a class of compounds that can inhibit the HIF-1 pathway.  Hsp90 plays 
an important role in the stabilization of HIF-1 under hypoxic conditions.43-45  Ansamycin deriva-
tives such as Geldanamycin (GA)46 and its analogues 17-allylamino-17-
demethoxygeldanamycin (17-AAG) or the water-soluble 17-dimethylaminoethylamino-17-
demethoxy-geldanamycin(17-DMAG) have been developed.  These inhibitors work by binding 
to Hsp90 and interfering with its function.47   GA binds to the N-terminal ATP binding domain of 
Hsp90 with high affinity and causes the destabilization and degradation of many Hsp90 client 
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proteins.48  Structural analyses show that the N-terminal domain of Hsp90 binds to GA and its 
derivatives in the N-terminal high-affinity ATP-binding site.49  Hsp90 binds to the HIF-1 PAS 
domain, and the Hsp90 inhibitors geldanamycin and 17-allylaminogeldanamycin (17-AAG) in-
duce proteasomal degradation of HIF-1 even in renal carcinoma cells that lack functional 
VHL.45, 50, 51   17-AAG is currently in phase I and phase II clinical trials.52, 53 
Inhibitors of topoisomerase (Top I) have also been identified as HIF inhibitors. Topoisome-
rases are enzymes that unwind and wind DNA, thereby controlling the synthesis of proteins for 
replication of DNA.  One such inhibitor, topotecan (TPT),54, 55 a campothothecin analogue56 was 
shown to inhibit the accumulation of HIF-1 protein.  Exploration of the mechanism of action of 
topotecan revealed that its inhibitory activity is independent of proteosomal degradation.  TPT 
inhibited HIF-1 even in the presence of protease inhibitors. TPT also did not affect the HIF-1 
mRNA accumulation but did decrease HIF-1 protein translation.  To address that Top I is re-
quired for inhibitory activity of HIF-1 of TPT, cells sensitive to campothecins (CEM) and cell re-
sistant to camptothecins (CEM-C2) cells were tested for transcription and protein accumulation 
of HIF-1 in a luciferase assay.  Addition of TPT to CEM cells showed a decrease in luciferase 
levels, whereas in CEM-C2 cells TPT had no effect on luciferase levels.  The researchers con-
cluded that Top I was required for inhibition of HIF-1 activity by TPT. In addition, it was shown 
that RNA transcription (not DNA replication) was required for inhibition of HIF-1 protein accu-
mulation by TPT. In essence, topotecan forms a stable covalent complex with the 
DNA/topoisomerase I complex, which leads to breaks in the DNA strand resulting in apoptosis.  
In 2007, GlaxoSmithKline was approved for hycamtin® by the FDA and TPT became the first 
Top I inhibitor approved for oral use. 
Also included in HIF-1 inhibitors are compounds that affect microtubule formation such as 
2-methoxyestradiol (2ME2).57  2ME2 inhibits tumor growth and angiogenesis by disrupting tu-
mor microtubules (MTs) in vivo.  2ME2 downregulates hypoxia-inducible factor-1 (HIF) at the 
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posttranscriptional level and inhibits HIF-1-induced transcriptional activation of VEGF expres-
sion.  Inhibition of HIF-1 occurs downstream of the 2ME2/tubulin interaction, as disruption of 
interphase MTs is required for HIF-1 downregulation.  The effects of 2ME2 on human prostate 
cancer cells PC-3 and human breast cancer cells MDS-MB-231 were examined.  Both PC-3 and 
MDA-MD-231 cells showed a reduction in nuclear and total HIF-1 protein. The inhibition of 
HIF-1 was dose dependent and seen under hypoxic and normoxic conditions.  It was also 
noted that VEGF protein levels were also reduced by 2ME2 in a dose-dependent manner.  To 
determine if the inhibition of VEGF was related to a direct effect on HIF-1, cells were trans-
fected with luciferase gene and under the control of hypoxia response elements from the VEGF 
promoter. The result showed that 2ME2 treatment activity also blocked the hypoxia-induced 
transcriptional activity of HIF-1. 
Examination of the effect of 2ME2 on HIF-1 on the post-transcriptional level using cyclo-
heximide (a post transcriptional inhibitor), showed that new protein synthesis was inhibited. 
Therefore, the decrease in HIF-1 levels in the presence of 2ME2 is due to degradation of HIF-
1 protein.   Lastly, the role of 2ME2 in microtubule depolymerization was also investigated.  
2ME2 treated PC-3 cells were labeled with antibodies against tubulin and HIF-1 and using a 
laser scanning confocal microscope, a dose dependent depolymerization of microtubules was 
observed in the 2ME2 treated cells compared to untreated control cells.  2ME2 displays a novel 
mechanism in which microtubules are depolymerized and HIF-1 protein levels as well as HIF 
transcriptional activity are downregulated independent of oxygen.  Also, at concentrations of 
2ME2 that inhibit tumor growth and vascularization, tumor microtubules are depolymerized. 
2ME2 has been established as a small molecule inhibitor of HIF-1. 
Thioredoxin (Trx-1) inhibitors PX-12 and pleurotin have also been identified as inhibitors of 
HIF-1 and VEGF.58  Welsh and colleagues investigated the effect of PX-12 and pleurotin on 
HIF-1.  These inhibitors decreased HIF-1 protein, HIF-1 trans-activation and expression of 
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HIF-1, VEGF and inducible nitric oxide synthase (iNOS) in vitro.  PX-12 and pleurotin inhibited 
the growth of MCF-7 cells with an IC50 of 1.9 ± 0.8 and 0.9 ±1.0 M, respectively and in HT-29 
cells of 2.9 ± 2.0 and 0.9 ±1.2 M, respectively.  Dose dependent decreases in HIF-1 protein 
in MCF-7 cells under hypoxic conditions when exposed to PX-12 and pleurotin were also ob-
served.  These inhibitors also decreased the expression of HIF-1 and VEGF proteins in vivo.  
The mechanism of the decrease in HIF-1 protein by these Trx-1 inhibitors is unknown.  How-
ever, it is clear that the mechanism does not involve pVHL since PX-12 and pleurotin decreased 
HIF-1 in RCC4 cells that lack pVHL. The authors suggest that either a Hsp90 or PI3K/AKT 
pathway may be involved, but were not investigated. 
Echinomycin59 has been shown to affect HIF-1 DNA binding.  Echinomycin inhibits HIF-1 
and HIF-1 DNA binding activity in a dose dependent manner.  Echinomycin was previously de-
termined to be a sequence-specific DNA binding agent.60  In that, it binds to the sequence 5'-
CGTG-3' of HRE consensus sequence 5'-R(A/G)CGTG-3'.  It was also shown that echinomycin 
inhibited hypoxic induction of luciferase in U251-HRE cells and VEGF mRNA expression in 
U251 cells. 
PX-478 is a HIF-1 transactivation inhibitors that reduces HIF-1 protein levels.  PX-478 (S-
2-amino-3-[4V-N,N,-bis(2-chloroethyl)amino]phenylpropionic acid N-oxide dihydrochloride) is an 
inhibitor of constitutive and hypoxia-induced HIF-1 levels (and thus HIF-1 activity).  Welsh et al. 
initially reported that PX-478 suppresses hypoxia induction of HIF-1 in cancer cell lines and 
suppresses constitutive HIF-1 in cells that have lost pVHL.61  PX-478 decreased hypoxia-
induced HIF-1 protein levels in many cancer cell lines.  The levels of constitutively elevated 
HIF-1 in Panc-1 pancreatic cancer and PC-3 prostate cancer and RCC4 renal cancer were 
also decreased. The elevated HIF in Panc-1 and PC-3 cells are due to increase in phosphatidy-
linositol 3-kinase/Akt signaling and HIF-1 gene amplification.  In RCC4 cells, elevated HIF is a 
result of loss of pVHL.  Therefore, the decrease in HIF-1 by PX-478 does not require oxygen 
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or pVHL.  The decrease in HIF-1 protein is accompanied by a decrease in HIF-1 transactivat-
ing activity and decrease in VEGF expression.  
Researchers also found that PX-478 inhibits HIF-1 in many levels by decreasing the level 
of HIF-1 mRNA, decreased translation of HF-1 protein in normoxic and hypoxic conditions 
and increased ubiquitination of HIF-1. It was suggested that the specificity of PX-478 on HIF-
1 may be the result of its cumulative effects on transcription, translation and ubiquitination. PX-
478 is a potent anti-tumor activity against HIF-1 expressing tumors. 
Some inhibitors of HIF-1 do not affect the mRNA levels or protein levels but inhibit the bind-
ing of HIF-1 to DNA and prevent the activation of transcription. One such compound is DJ12.  
DJ12 was identified as a HIF-1 inhibitor by the screening of 15,000 compounds.62  The com-
pounds were screened using Chinese hamster ovary cells, which were designed to stably ex-
press luciferase reporter construct under the control of a hypoxia response element.  DJ12 inhi-
bited VEGF in breast cancer cell lines MDA-468 and ZR-75, melanoma cell line MDA-435, and 
pVHL mutant renal cancer cell lines RCC4 and 786-0.  DJ12 down-regulates mRNA of down-
stream targets of HIF-1, and significantly inhibited HIF-1 transactivation activity by blocking 
HIF-1 hypoxia response element-DNA binding.  The researchers suggested that DJ12 may 
work by inhibition of HIF-1 transactivation through the blocking of HIF-1 HRE DNA binding. 
DJ12 also showed 45% inhibition of HIF-1 DNA binding from nuclear extracts of hypoxic MDA-
468 cells treated with 100 mol/L of DJ12.  Direct addition of DJ12 to nuclear extracts contain-
ing constitutive expression of HIF-1 had no effect in blocking HIF-1 HRE-DNA binding, sug-
gesting that DJ12 does not directly interfere with the formation of protein-DNA complex but may 
inhibit the formation of HIF-1, HIF-1, and CBP/p300 transcription complex or folding of HIF-
1.  Hence, DJ12 has been introduced as a novel HIF inhibitor that is effective against the HIF 
pathway for breast, renal and melanoma cancer cell lines.  However, as with many HIF inhibi-
tors, long term (16 hours) toxicity assay studies revealed that DJ12 was toxic to MDA-468 cells 
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at IC50 of 191mol/L in normoxic cells and greater than 250 mmol/L in hypoxic cells.  Toxicity 
was attributed to multiple HIF targets by these compounds.  
Other mechanisms that decrease HIF-1 protein levels, include cyclin dependent kinase in-
hibitor, Flavopiridol.63  Flavopiridol is a potent cyclin-dependent kinase inhibitor that has an ef-
fect on VEGF.  As previously discussed, VEGF secretion is important for the angiogenesis and 
vascular proliferation in cancer cells and VEGF is under the control of HIF-1 gene expression. 
Newcomb and co-workers has investigated the effect of flavopiridol on U87MG and T98G gli-
omas cells lines.63  Flavopiridol has shown anti-angiogenic properties by inhibition of VEGF, de-
creased tumor cell migration, decreased hypoxia HIF-1 expression and reduced vascularity in 
Gl261 glioma cells in animals treated with Flavopiridol.  
Another inhibitor, chetomin is a member of the epidithiodiketopiperazine (ETP) family, (spe-
cifically from the fungus Chaetominum species) and was initially shown to have antimicrobial 
activity.64, 65  CBP/p300 is required for the coactivation of HIF.66-69  Chetomin has been shown to 
be a disrupter of HIF binding to p300 and works by disrupting the structure of the cysteine-
histidine-rich domain 1(CH1) domain of p300 and interferes with its interaction with HIF and 
therefore HIF-1 transcription and inhibited tumor growth.70  More recently, it was shown that 
chetomin reacts with p300, causing zinc ion ejection.71  It was proposed that compounds such 
as chetomin cause zinc ion ejection via a mechanism related to other known zinc binding dis-
rupting compounds72 in which a zinc-binding cysteinyl thiol reacts with the torsionally strained 
disulfide of the ETP core to generate a transient protein-ETP disulfide. This disulfide can then 
rearrange to form an intramolecular protein disulfide with consequent reduction in zinc ion affini-
ty.  The ejected zinc ion (or zinc ETP complex) can then complex with a second ETP core to 
form a stable complex. 
Other inhibitors include the histone decaceylase (HDAC) inhibitor, FK228, a bicyclic peptide, 
has also been shown to inhibit HIF-1 activity under hypoxic conditions, as well as inhibit tumor 
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angiogenesis.73 Bortezomib, which functions by interfering with the carboxyl-terminal transacti-
vation domain of HIF-1 74 and the antifungal drug amphoteric B that inhibits HIF-1 by inducing 
the interaction of HIF-1 with (FIH-1), leading to decreased recruitment of p300.75 
It is clear from the large number of HIF inhibitors in the literature that HIF-1 is a viable target 
for anti-tumor therapy.  Thus far, there has been no small molecule that directly inhibits HIF-1.  
Therefore, our goal is to design and synthesize small molecule inhibitors of HIF-1. 
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2 DESIGN AND SYNTHESIS OF SMALL MOLECULE INHIBITORS OF HIF-1 
 
2.1    Background 
It has already been established in the literature that inhibition of HIF-1 with small molecules 
can have an anti-tumor effect (briefly reviewed in chapter 1.2).  However, a specific HIF-1 path-
way inhibitor was yet to be discovered.   Therefore, the Van Meir laboratory at Emory University 
initiated a random screen of 10,000 compounds from a  2,2-dimethylbenzopyran combinatorial 
library.76  The benzopyran moiety was chosen because it appears in more than 4000 natural 
compounds and is considered to be lipophilic enough to cross the blood-brain barrier.76  The 
library was screened using an HRE-alkaline phosphatase assay developed by the Van Meir 
lab.77-79  In this assay, LN229 tumor cells were stably transfected with the alkaline phosphatase 
reporter, driven by 6 copies of the HRE (hypoxia response element) for the VEGF gene.  This 
initial screening provided a few hit compounds, from which one compound, KCN-1 (Figure 2) 
was chosen for further evaluation. KCN-1 had an average IC50 of 4 M using the HRE-alkaline 
phosphatase assay.   
O
N
SO2
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Figure 2.  Four regions for synthetic modification of KCN-1 
 
Next, preliminary in vivo experiments were performed to determine the anti-tumor effec-
tiveness of KCN-1 (Narra Devi, Emory University).  Nude mice (8 per group) were implanted 
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with LN229 tumor cells on both hind flanks.  After 1 week, one group of mice was subjected to 
peritoneal injection of KCN-1 (60 mg/kg; 5 days/week), while the other group received the ve-
hicle.  The mice injected with KCN-1 showed tumors that weighed 6-fold less than that of the 
mice treated with vehicle (Figure 3).  In addition, the KCN-1 injected mice displayed no apparent 
signs of toxicity or other negative effects.  
 
  
       A               B 
Figure 3.  KCN1 inhibits LN229 glioma xenograft growth. LN-229 was implanted in both flanks of 
nude mice (8/group) and 1 week later started intraperitoneal injections of KCN1 (60 mg/kg; 5 
days/week).  A. Tumor volume over time.  B. Tumors weighed 6-fold less at termination in KCN1 
group. (This figure courtesy of the Van Meir lab). 
 
Motivated by the encouraging results from both the in vitro inhibition assay and the in vi-
vo experiments with mice, optimization of the structure of KCN-1 molecule was an obvious next 
step.  Our goal was to improve the potency and the physiochemical properties of these inhibi-
tors through design and synthesis of analogues.   That is, the new analogues should possess 
properties that are predicted to lead to oral bioavailability, chemical and metabolic stability and 
minimal toxicity.   
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 The first property to consider is solubility.  All compounds have to be water-soluble (to 
various degrees) in order to be active. This is in addition to the need for solubility for reasons 
such as formulation, delivery, and membrane penetration. For membrane permeation consid-
erations, compounds should possess an optimal solubility in both water and fat.  It needs to be 
lipophilic enough to cross the cell membrane and enter into the cell, as well as water soluble 
enough to be transported in the aqueous media such as blood and cellular fluid.   In addition, 
low water solubility can hinder absorption and activity.   The water solubility is related to polarity, 
charge, molecular size, and the number of hydrogen bond donors in the molecule.  Too many 
hydrogen bond donors can lead to low lipophilicity such that the drug cannot penetrate the cell 
membrane.   LogP is a measure of the lipophilicity of a molecule.  LogP is determined by the 
ratio of the solubility of the compound in 1-octanol versus water. The more positive the logP is 
the more lipophilic compound is.  Ionization is also a factor in lipophilicity, since at physiological 
pH (7.4), amines are normally protonated and carboxylic acid deprotonated.  Such ionizations 
may hinder the drug from crossing the cell membrane.  However, this problem can be solved by 
adding electron-withdrawing groups (to lower pKa) or electron-donating groups (to increase pKa) 
of the molecule. 
There are other important features that are desirable in an orally bioavailable drug.   
Christopher Lipinski has complied some of these properties in ”the rule of 5”80  This rule of 
thumb is used by medicinal chemists to evaluate the drug-likeness of a molecule.  It is based on 
the statistical analysis of a large database of known drugs.  According to the Lipinski “rule of 5,” 
compounds that are most likely to become a drug have the following features:  Not more than 5 
hydrogen bond donors (oxygen and nitrogen molecule attached to at least one hydrogen), no 
more than 10 hydrogen bond acceptors,  a molecular weight under 500 and a logP of less than 
5.  These properties are associated with 90% of orally active drugs that have achieved phase II 
clinical status.  Although following this rule is no guarantee that a compound will be active, it 
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provides a good starting point. There are many other sophisticated studies that allow for evalua-
tion of the drug-like properties of a compound.81 
Toxicity is also an important consideration in drug design as many drug candidates are 
withdrawn for unforeseen toxicity.  The metabolism of certain functional groups can lead to 
products that result in toxicity.  For example, N-hydroxylation on the amine nitrogen of anilines 
can lead to the formation of N-hydroxylamine metabolites that eventually form reactive nitrosa-
mine intermediates.  Also, hydrazines can lead to metabolites that can cause hepatoxicity.  
Benzene rings can also present a problem, since they can potentially undergo enzymatic epoxi-
dation to form an electrophilic arene oxide that is toxic.  Michael acceptors such as - unsatu-
rated carbonyls are also avoided because they are very reactive and toxic.  Compounds con-
taining alkyl halide are also problematic because halides are good leaving groups and are sus-
ceptible to nucelophilic attack.  Alkenes can also lead to toxic products after they undergo me-
tabolic epoxidation.  These are only some of the functional groups that can cause toxicity. How-
ever, the presence of some of these functional groups does not necessarily mean that a com-
pound will not make a good drug candidate.82 
Keeping all of these general considerations about physiochemical properties and toxicity 
in mind, our goal was to design and synthesize analogues of KCN-1.  Our approach was to sys-
tematically modify KCN-1 along four regions of the molecule as shown in Figure 2.  Each region 
of KCN-1 was modified separately to see the effect that these modifications will have on activity.  
As a result, we hoped to generate potent compounds, as well as develop a structure-activity re-
lationship (SAR).   
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Figure 4.  Analogues designed and synthesized 
 
In all, seven classes of compounds were synthesized (Figure 4).  The sulphonamide 
group of Region I was either eliminated (Class 1) or replaced by an amide group (Class 7).  Re-
gion II and III was modified with several alkyl and aryl substitutions using known synthetic pro-
cedures (Class 2).  Namely, the aldehyde derivative of the core structure of region I underwent 
reductive amination with a variety of alkyl and aryl primary amines to provide modifications to 
region II.   Then, sulfonylation of the resulting secondary amines with various sulfonyl chlorides 
allowed modifications to region III (Figure 4).   The benzopyran ring of region IV was probed to 
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determine the influence of subtle and major modifications of this region on activity.  The first 
modification was the replacement of the gem-dimethyl group of region IV with a 2-Ethyl-2-
methyl group (class 3).    The benzopyran ring of region IV was also replaced with a quinoline 
ring (class 4) and benzofuran ring (class 5).  Finally, the benzopyran ring of region IV was re-
placed with a pyranopyridine ring to generate classes 6a, 6b and 6c.   
 
2.2  Results and Discussion 
2.2.1  Chemistry 
Class 1:   Benzopyran analogues A 
For the synthesis of the class I analogues, the benzopyran moiety was retained, while the 
sulphone group as well as the 3,4-dimethoxyphenyl group was eliminated.  To afford these ana-
logues, the aldehyde derivative of the benzopyran moiety was synthesized followed by reductive 
amination and methylation of the resulting secondary amine (in some cases).   
The synthesis of class I analogues began with compound 1 that was synthesized according to 
literature procedures.83  Reductive amination of 1 with several primary amines gave analogues 
2.  Methylation of secondary amine 2 with MeI and NaH generated analogues 3 (Scheme 1) 
 
O
CHO
O
H
N
R1
O
N
R1
Me
2
a b
1 3
 
R1 =  3,4-dimethoxyphenyl (2a, 3a), 2-pyridinyl (2b, 3b), 2,4-dimethylphenyl (2c, 3c), 4-
carboxyphenyl (2d), 2-bromophenyl (2e), 2-fluorophenyl (2f) 
 
Reagents and Conditions: (a) R2NH2, ZnCl2, NaCNBH3, r.t.; (b) MeI, NaH, THF, r.t. 
 
Scheme 1.  Synthesis of benzopyran analogues A 
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Class 2:  Benzopyran analogues B 
Next, modifications were separately made to region II (5a – 5j) and then to region III (5k – 5q) 
of KCN-1 with various alkyl and aryl substituent, in order to probe their effect on activity.    Re-
ductive amination of aldehyde 1 with various aryl or alkyl amines afforded compound 4 that was 
subsequently sulphonated with various sulfonylchlorides to give analogues 5 (Scheme 2).   
 
 
O
CHO
O
H
N
R1
O
N
R1
SO2
R2
5
a b
41
 
R2 = 3,4-dimethoxyphenyl and  
R1 = isopropyl (5a), propargyl (5b), butyl (5c), t-butyl (5d), allyl (5e), 2-pyridinyl (5f), isobutyl 
(5g), cyclopentyl (5h), cyclopropyl (5i), cyclohexyl (5j)  
 
R1 = phenyl and  
R2 = 4-methoxyphenyl (5k), 2,4-dimethylphenyl (5l), 2,4-dichlorophenyl (5m), 2-trifluoromethoxy-
4-bromophenyl (5n) 
 
Reagents and Conditions: (a) R1NH2, ZnCl2, NaCNBH3, r.t.; (b) R2SO2Cl, Et3N, DCM, r.t. 
 
Scheme 2.  Synthesis of benzopyran analogues B 
 
Class 3:  2-Ethylmethyl benzopyran analogue 
Next, class 3 analogues were generated that involved a slight modification to the benzopyran 
portion (Region IV) of KCN-1.   The ethyl group replaced one of the gem-dimethyl group on the 
benzopyran ring (Scheme 3).  For the synthesis of these analogues, O-alkylation of 4-
hydroxybenzophenone 6 with 3-methylpentyn-3-ol afforded compound 7.  Claisen rearrange-
ment and re-aromatization of 7 by microwave irradiation yielded compound 8.  Reductive amina-
tion of aldehyde 8 gave the secondary amine 9 that was sulfonated with 3, 4-
dimethoxybenzenesulfonyl chloride to give the final product 10. 
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Reagents and Conditions: (a) 3-Methyl-pent-1-yn-3-ol DBU, TFAA, CuCl, CH3CN, 0 °C to r.t., 
32%; (b) xylene, microwave (220 W, 200 torr, 120 °C, 100 min; (c) aniline, ZnCl2, NaCNBH3, r.t., 
overnight, 40%; d) 3,4-dimethoxybenzylsulfonyl chloride, Et3N, DCM, r.t., 24 h. 
Scheme 3.  Synthesis of 2-ethyl-2-methylbenzopyran analogue 
 
Class 4:  Quinoline analogues 
The next modification to region IV was the replacement of the benzopyran ring with another 
fused ring system - quinoline (Scheme 4).  Commercially available quinoline aldehyde 11 was 
subjected to reductive amination, followed by sulfonylation to afford compound 13.   
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Reagents and Conditions: (a) aniline, ZnCl2, NaCNBH3, r.t.; (b) 3,4-dimethoxybenzylsulfonyl 
chloride, pyridine. r.t. 
 
Scheme 4.   Synthesis of quinoline analogue  
 
Class 5:   Benzofuran analogues 
Additionally, the 2,2-dimethylbenzopyran ring (Region IV) of KCN-1 was replaced with a 2,2-
dimethylbenzofuran ring (Scheme 5).  Commercially available 2,2-dimethyl-2,3-
dihydrobenzofuran-5-carbaldehyde 14 was treated by reductive amination with various primary 
amines to give compound 15 and then sulfonylation with 3,4-dimethoxybenzenesulfonyl chloride 
to give analogues 16. 
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1514
 
R1 = phenyl (16a), cycloheptyl (16b), isopropyl (16c), butyl (16d), cyclohexyl (16e), cyclopentyl 
(16f)  
 
Reagents and Conditions: (a) R1NH2, ZnCl2, NaCNBH3, r.t., 2 h; (b) 3,4-
dimethoxybenzenesulfonyl chloride, Et3N, DCM, r.t. 
 
Scheme 5.   Synthesis of benzofuran analogues 
 
Class 6: Pyranopyridines 
We also replaced one of the carbons on the aromatic portion of the benzopyran ring with ni-
trogen to afford pyranopyridine analogues.   The pyridine nitrogen was separately placed in 
each of the three available positions on the benzopyran ring.  It was envisioned that these com-
pounds would provide increased water solubility and additional interaction points and therefore 
increased activity. 
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The first of these compounds was the pyrano(2,3b)pyridines 20.  The 2H-pyrano-[2,3b]-
pyridine core 17 was synthesized as previously described.84  Formylation of 17 with BuLi and 
DMF gave compound 18.  Reductive amination with aniline (19a) or cyclohexylamine (19b) fol-
lowed by sulfonylation with 3,4-dimethoxybenzesulfonyl chloride afforded compounds 20a and 
20b (Scheme 6). 
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R1 = phenyl (20a), cyclohexyl (20b) 
 
Reagents and Conditions:  (a) (i) BuLi, -78 °C (ii). DMF, anhydrous ether; (b) R1NH2, ZnCl2, 
NaCNBH3, MeOH; (c) 3,4-diethoxybenzenesulfonyl chloride, Et3N, DCM, r.t. 
 
Scheme 6.   Synthesis of pyrano(2,3b)pyridine analogues 
 
The second set of analogues in this class was the pyrano(3,2b)pyridines that were prepared 
using the following procedure.  O-alkylation of commercially available 2-bromo-5-
hydroxypyridine 22 followed by Claisen rearrangement and formylation gave compound 24 in 
23% overall yield for two steps.  Subsequent reductive amination of 24 and then reaction of 
secondary amine 25 with various sulfonyl chlorides gave analogues 26 (Scheme 7). 
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R2 = 3,4-dimethoxyphenyl and 
R1 = phenyl (26a), butyl (26b), 3,4-dimethoxyphenyl (26c), cyclopentyl (26d), cyclohexyl (26e), 
tetrahydranapthyl (26f), cycloheptyl (26g), cyclooctyl (26h), cyclobutyl (26i)  
 
R1 = phenyl and 
R2 = cyclohexyl (26j), isopropyl (26k), butyl (26l), propyl (26m), isobutyl (26n), 4-biphenyl (26o), 
propyl (26p), benzodioxolyl (26q), 2,3-dihydrobenzo(1,4)dioxinyl (26r), 4-fluorophenyl (26s)  
  
Reagents and Conditions: (a) 2-methylbut-3-yn-2-ol, TFAA, DBU, CH3CN; (b) xylene, micro-
wave heating 120 °C, 30 min; (c) 1.BuLi,  2.DMF, anhydrous THF; (d) R1NH2, ZnCl2, NaCNBH3, 
MeOH; (d) R2SO2Cl, Et3N, DCM 
 
Scheme 7.  Synthesis of pyrano(3,2b)pyridine analogues 
 
The final pyranopyridine derivative was the pyrano(2,3c)pyridines (class 6c).  These 
analogues were synthesized by Hui Jin.  To synthesize these analogues, 2-hydroxy-5-methyl 
pyridine 28 was brominated to afford compound 28.  The N-oxidation of 28 with m-CPBA gave 
product 29 in 70% yield.  Rearrangement of 29, facilitated by TFAA afforded compound 30.  O-
alkylation of 30 with 3-chloro-3-methyl-1-butene followed by Claisen rearrangement gave com-
pound 32.  Substitution of the primary alcohol 32 with bromine followed to give 33. Subsequent 
nucelophilic substitution of 33 with various primary amines followed by sulfonylation with appro-
priate aryl sulfonylchlorides resulted in analogues 36 (Scheme 8). 
 
22 
 
O
N
N
R1
O2S
R2
O
N H
N
R1
36
O
N
Br
HO
N
HO
N
O
HO
N
Br Br
Br Br
O
N
Br
OH
O
N
OH
Br
O
N H
N
R1
a b c
d e
f
g h
i
27 28 29 30
31
33 34
32
35
HO
N
Br
OH
 
R1 = phenyl and R2 = 4-methoxyphenyl (36a), 4-nitrophenyl (36b)  
R1 = cyclohexyl and R2 =4-isopropylphenyl (36c), 3,4-dimethoxyphenyl (36d) 
Reagents and Conditions: (a) Br2, pyridine, 0°C, 74%; (b) m-CPBA, THF, 70%; (c) 1. TFAA, 2.  
MeOH, 30%; (d) 3-chloro-3-methyl -1-butene, K2CO3, KI, CuCl2, acetone (e) CuCl, toluene,  mi-
crowave heating (200W, 120°C, 1h); (f) CBr4, PPh3, DCM, 40 %; (g) DIEA, DMF; (h) BuLi, THF, 
-78°C, (i) pyridine, r.t. 
 
Scheme 8.  Synthesis of pyrano(2,3c) pyridine analogues 
 
Class 7:  Amide analogue 
Finally, we replaced the sulphonamide of compound 26a with an amide group.  An amide group 
is common bioisostere for sulfonamide and may enhance activity.  In this case, the previously 
synthesized 25a was reacted with 3,4-dimethoxybenzoyl chloride in the presence of triethyla-
mine to give the product 37 in 98% yield (Scheme 9). 
 
23 
 
O
N
N O
OMe
OMe
O
N
N
H
OMe
OMeC
O
Cl
Et3N
DCM
98%
25a 37  
 
Scheme 9.  Synthesis of amide analogue 37 
 
2.2.2 Biology 
The generated analogues of KCN-1 were screened using a human glioma cell line LN229-HRE-
AP, which stably expresses a hypoxia-responsive luciferase reporter gene.   The IC50 values of 
all compounds were calculated based on a concentration curve testing of compounds at 0, 1, 5, 
10 and 25 M.  The compounds were tested in triplicate.   KCN-1 was tested along with the oth-
er analogues.   Since the compounds were not all tested in a single experiment, the value of 
KCN-1 ranged from 0.3 -1.3 M, with an average IC50 of 0.7 ± 0.4 M.   
Class I (benzopyran A) analogues were designed to probe the importance of the sul-
phone group.   In general, the loss of the sulphone group in compound 2a - 2f and 3a - 3c re-
sulted in a marked decrease in activity (Table 1).  For secondary amine compounds 2a - 2f, only 
2a and 2b had IC50 values below 10 M, the others were higher than 25M (beyond the scope 
of the experiment).  The best compound in that series was the 3,4-dimethoxyphenyl derivative 
2a with an IC50 of 3.0 M.    Analogues 3a - 3c showed similar IC50 as their secondary amine 
counterparts 2a - 2c, with the exception of the 2,4-dimethoxyphenyl derivative 3c that had an 
IC50 of 2.6 M.  Therefore, methylation of the secondary amine did not seem to make much of a 
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difference.   As a result, it was concluded that the sulfone group was essential to the activity of 
these compounds and was retained in future modifications of KCN-1. 
 
Table 1.  Structures and activities of analogues 2 and 3a 
O
N
R1
R2
 
compound R1 R2 
IC50 
(M)  compound R1 R2 
IC50 
(M) 
2a H 
MeO OMe 
3.0  2f H F
 
>25 
2b H 
N
 
8.5  3a Me 
MeO OMe
5.0 
2c H 
 
>25.  3b Me N
 
8.4 
2d H 
COOH  
>25  3c Me 
 
2.6 
2e H 
Br
 
>25      
aResults were from single runs 
 
Next, Region II of the molecule was probed with various alkyl and aryl substituent (5a – 5k).   
All the compounds were active to some extent (Table 2).  The best of this group was the pro-
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pargyl derivative 5b, iso-butyl derivative 5g and the cyclopropyl derivative 5i with IC50 values of 
1.3, 1.6 and 1.5 M, respectively.   In general, longer branched alkyl chains such as the iso-
butyl group of 5g (1.6 M) tended to do better than long unbranched chains such as the butyl 
group of 5c (3.3 M) or shorter branched chains as the tert-butyl group of 5d (3.5 M).  Surpri-
singly, the pyridinyl substituted compound 5f was almost more than 5 fold lower in activity than 
KCN-1, which is substituted by a phenyl group at the same position.  Also, alkyl rings smaller 
than 6 carbons were better tolerated. 
 
Table 2.   Structures and activities of analogues 5a – 5ja 
O
N
R1
SO2
OMe
OMe  
compound R1 
IC50 
(M)  compound R1 
IC50 
(M) 
5a 
 
3.1  5f 
N
 
5.0 
5b 
 
1.3  5g 
 
1.6 
5c 
 
3.3  5h 
 
 
0.5 
 
5d 
 
3.5  5i 
 
1.5 
5e 
 
3.4  5j 
 
4.0 
aResults were from single runs 
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Compound 5k – 5u, were modified at region III of KCN-1 with various aryl substitutions (Table 
3).  The best compound in this group was the 4-methoxyphenyl substituted 5k and 2,4-
dimethylphenylsubsituted 5i with IC50 values of 0.6 and 0.5 M, respectively.  The 2-
trifluoroester 4-bromo phenyl substitution (5p) resulted in a significant decrease in activity as 
compared to 5m that was only a 4-bromosubstituted that had relatively better activity with an 
IC50 of 5.5 M.  . 
 
 
Table 3.   Structures and activities of analogues 5k – 5oa 
O
N R2
 
compound R2 
IC50 
(M)  
5k 
OMe  
0.6 
 
 
5l 
 
0.5  
5m 
Cl
Cl  
2.1  
5n 
F3CO Br
 
>25  
aResults were from single runs 
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Compound 10 represented a subtle change to region IV of the KCN-1 molecule.  In this case, 
simply substituting one of the gemdimethyls of the benzopyran ring system of KCN-1 with an 
ethyl group resulted in a decrease in activity with an IC50 of 2.2 M (Table 4).   
 In the case of compound 13, replacement of the benzopyran ring of KCN-1 with a quinoline 
ring led to a reduction in activity against HIF-1 with an IC50 of 3.5 M (Table 4).  
 
Table 4.   Structures and activities of analogues 10 and 13a 
 
R1 N SO2
OMe
OMe  
compound R1 
IC50 
(M) 
10 O 3.1 
13 
N
 
1.3 
     aResults were from single runs 
 
  The benzofuran derivatives 16 afforded some potent compounds (Table 5).  A compari-
son of compound 16a (IC50 = 0.5M) to KCN-1 shows that the substitution of the benzopyran 
ring with benzofuran did not necessarily result in a more potent compound than KCN-1, but the 
benzofuran analogue was comparable to that of KCN-1.  The foreseeable benefit of the benzo-
furan structure of 16 is that it eliminates the double bond on the pyran ring of KCN-1.  Since that 
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double bond may be susceptible to substitution in vivo and thereby introduce toxicity, the benzo-
furan ring may be a better alternative.   The ring size of the cycloalkyl derivatives seems to have 
an effect on activity. A comparison of the cycloheptyl ring of 16b (9.1 M), the cyclohexyl ring of 
16e (8.2 M )and the cyclopentyl ring of 16f (0.4 M) seems to suggest that smaller rings (ring 
size 5 or smaller), tend to be more favorable that large rings (6 carbons or more).  This is similar 
to the trend seen with the benzopyran analogues B (class 2). 
 
Table 5.  Structures and activities of analogues 16a 
O
N
R1
SO2
OCH3
H3CO
 
compound R1 IC50  compound R1 IC50 
16a 
 
0.5  16d 
 
0.6 
16b 
 
9.1  16e 
 
8.2 
16c 
 
1.5  16f 
 
0.4 
aResults were from single runs 
 
 
The first of the pyranopyridine analogues was Class 6a, the pyrano(2,3b)pyridines.  Only 
two compounds were designed in this class.  Compound 20a had the same substitutions as 
KCN-1 with the exception of the pyranopyridine core.  This compound showed some activity 
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with an IC50 of 2.5 M.  However, it was not as active as KCN-1.   Replacing the phenyl ring by 
the cyclohexyl ring (20b) resulted in a loss of activity, that is, the IC50 was higher than 25 M 
(Table 6). 
 
Table 6.  Structures and activities analogues 20a 
O N
N
R1
O2S
OMe
OMe
 
compound R1 IC50 (M) 
20a 
 
2.5 
20b 
 
>25 
                                                   aResults were from single runs 
 
 
The next group of compounds in this class was the pyrano(3,2b)pyridine (class 6b). Com-
pounds 26a – 26k were modified at region I with various alkyl and aryl amines. This class of 
compounds was among the best in the pyranopyridine class (Table 7).   All of these compounds 
showed inhibitory activity against HIF-1 with the exception of the 2,4-dimethoxy derivative 26c.   
Phenyl derivative 26a is similar in structure to KCN-1 with the exception of the pyra-
no(3,2b)pyridine core.  This compound had an IC50 of 1.3 M, which is within the range of activi-
ty for KCN-1.   The best compound in this group (26a – 26t) was the cyclobutyl derivative 26i 
with an IC50 of 0.25 M.  Comparing all the cycloalkyl analogues, the general trend remained 
about the same as that of other series, in that smaller rings (< 6 carbons) tend to have better 
activity than larger ring derivatives (> 6 carbons). The tetrahydronaphthalene derivatives 26f 
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and the 4-flurophenyl derivative 26j had the lowest activity in this series with IC50 of 6.15 and 7.7 
M, respectively. 
Additionally, these pyrano(3,2b)pyridines 26k – 26t was also modified at region III with alkyl 
and aryl sulphonyl derivatives.  Generally, this group did not produce very active compounds 
(Table 8).  The cyclohexyl derivative 26i was well tolerated in this position, with an IC50 of 0.4 
M.  In this case, the smaller cyclopropyl ring showed almost no activity within the experimental 
conditions.  Compound 26r and 26t was an attempt to fix the conformation of the 2,4 dimethox-
ybenzene to see if it would enhance activity.  Compound 26r that separated the oxygen atoms 
by one carbon showed a decrease in activity (IC50 = 6.5 M) compared to the 3,4 dimethoxy 
substituted compound 26a (1.25 M).  However 26t, in which the oxygen atoms are separated 
by 2 carbons showed an IC50 of 0.85M.  Also noted is the quinoline derivative 26s that showed 
relatively good activity with an IC50 of 0.9 M. 
 
Table 7.  Structures and activities of analogues 26a – 26ja 
O
N
N
R1
O2S
OMe
OMe
 
Compound R1 IC50 (M)  Compound R1 IC50 (M) 
26a 
 
1.3  26f 
 
6.2 
26b 
 
0.9  26g 
 
6.6 
31 
 
26c 
OMe
OMe
 
>25  26h 
 
0.7 
26d 
 
0.6  26i 
 
0.25 
26e 
 
0.8  26j 
F  
5.7 
aResults were from single runs 
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Table 8.  Structure and activities of analogues 26k – 26ta 
O
N
N
O2S
R2
 
Compound R2 IC50 (M)  Compound R2 IC50 (M) 
26k 
 
0.4  26p 
 
0.88 
26l 
 
13.4  26q 
 
3.4 
26m  >25  26r O
O
 
6.5 
26n 
 
5.0  26s 
N
 
 
0.9 
26o 
 
6.4  26t 
O
O
 
0.9 
aResults were from single runs 
 
The third group of compounds in class 6 was the pyrano(2,3c)pyridinyl derivatives (class 6c).  
These compounds also showed good activity and were comparable to KCN-1 (Table 9).   Deriv-
atives 36a, 36b and 36c all showed similar IC50 values of 1.42, 1.80 and 1.08 M, respectively.  
The cyclohexyl derivative 36d was similar to other series of compounds with a much lower IC50 
of 5.8 M. Comparing 36c to 36d, the isopropylphenyl derivative (36c) allowed for improvement 
in activity compared to the 3,4 dimethoxy substitution of 36d. 
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Table 9.  Structures and activities analogues 36a 
O
N
N
R1
O2S
R2
 
compound R1 R2 IC50 (M) 
36a 
 OMe  
1.4 
36b 
 NO2  
1.8 
36c 
 
 
1.1 
36d 
 OMe
OMe
 
5.8 
aResults were from single runs 
 
Because the pyranopyridine analogues were among the best compounds, we decided to 
replace the sulphonamide group with an amide group to see what effect this modification will 
have on activity.  The amide derivative showed a 2-fold increase in activity over the sulphona-
mide derivative (Figure 5).  This amide group can be incorporated in future modifications of the 
compound. 
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Figure 5.  Comparison of structures and activities of 26a and 37 
 
2.3 Summary of analogues designed and synthesized 
Several potent analogues of the lead compound KCN-1 were synthesized.  These ana-
logues were able to yield information on the important functional groups at each of the four re-
gions indentified in Figure 1.  This has allowed us to make some general conclusion about the 
SAR of this molecule (Figure 4).  Analogues 2 showed that the sulphone group was required for 
the activity of these compounds.  Also, alkyl rings 5 carbons or shorter, as well as longer 
branched chains were well tolerated at region II of KCN-1.  At region III, aryl substitutions seem 
to be better than alkyl substitutions.  The benzofuran analogues (16) were also successful in 
that the analogues in this series of analogues showed activity comparable to that of KCN-1, but 
may be a good future alternative to the benzopyran derivatives, since it does not contain an 
electrophilic double bond.   To date, the pyrano(3,2b)pyridine analogues provided the most im-
provement in activity as compared to KCN-1. The best overall compound came from this group 
– the cyclobutyl derivative 26i, that had an IC50 of 0.25 M. The improvement in activity of these 
analogues over KCN-1 may be a result of increased hydrophilicity and/or hydrogen bond inte-
ractions from the addition of the pyridine ring. 
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Figure 6.  Structure-activity relationship of KCN-1 
36 
 
3 MECHANISTIC STUDIES 
In addition to the synthesis of more potent analogues of KCN-1, another goal was to deter-
mine the mechanism of action of these compounds.  The following discussions will emphasize 
our synthetic efforts toward this goal, along with biological work by the Van Meir laboratory. 
Initial investigation into the mechanism of action of KCN-1 by the Van Meir lab suggested 
that KCN-1 specifically affects the HIF pathway without affecting common signal transduction 
pathways in the cell (Figure 7).  Cell extracts of normoxic and hypoxic cells were analyzed for 
changes in total protein expression levels in the presence of KCN-1.  The extracts were ana-
lyzed by Western blot at 5 hours (when strong anti-HIF-1 activity is detected). No changes 
were observed for signal transduction proteins (Akt, p85 PI3K subunit, Erk1/2), short-lived pro-
teins (p53, IkBa, cyclin D1) or control proteins (HIF-1 and actin). Western blot analysis also 
showed that KCN-1 inhibits the synthesis of HIF-1 under hypoxic but not normoxic conditions 
(data not shown).  This suggests that KCN-1 has a unique mechanism of action targeting a 
component of the HIF translation machinery operating specifically under hypoxia.  KCN-1 is 
shown to prevent HIF-1 stabilization under hypoxia within 5 hours, while they do not perturb 
main cellular signaling events or stability of other short-lived proteins in the cells during the 
same time frame.   
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Figure 7.  Analysis of specificity of KCN1. LN229 cells were pre-treated with KCN1 (25 M for 
1h and then put in 1% O2 for 5 hrs). Cell extracts were analyzed by Western blot for levels of 
total proteins. (This figure, courtesy of the Van Meir lab) 
 
To further investigate the mechanism of action of KCN-1, we attached a linker to KCN-1 
that can be coupled to a variety of amine reactive moieties such as an agarose matrix or a fluo-
rophore.  These linker-modified versions of KCN-1 can then be used in pull-down assays to 
identify any interacting proteins from cell lysates.     
Next, we probed the structure of KCN-1 for a convenient place of attachment to the linker 
that will not significantly affect its activity.  KCN-1 was selectively demethylated at the para posi-
tion in the presence of thiophenol.  The resulting derivative 38 was shown to be approximately 
80% as active as the unmodified KCN1 in the HRE-AP assay, suggesting that this modification 
allowed the molecule to retain much of its activity.  We then attached a 4-carbon linker with a 
terminal Boc-protected amine.  The Boc-modified compound also retained the majority of the 
activity of KCN-1.  The next step was simply to attach the linker to an immobile solid phase after 
removal of the Boc protecting group.  However, removal of the Boc group using TFA resulted in 
cleavage and/or alteration of the KCN-1 molecule.  Therefore, a different strategy for successful 
synthesis of the primary amine was employed (Scheme 8).   
The hydroxyl group of the demethylated compound 38 was alkylated with 1-bromo-4-
phthalimidebutane to give 39.  Deprotection of the phthalimide group with hydrazine afforded 
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the free amine 40 that can then be coupled with an amine reactive derivative such as a fluoro-
phore or agarose beads. 
For coupling to the agarose bead, the linker modified compound was mixed with Pierce 
ReactiGel (6x) 1,1-carbonyldiimadazole-activated 6% cross-linked beaded agarose (50 mol/ml) 
and attached through the amine group (Scheme 8).  The remaining carbonylimidazole residues 
of the agarose beads were subsequently quenched with ethanolamine.  A control matrix was 
also generated through the reaction of the activated agarose with ethanolamine alone. 
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d
 
  Reagents and Conditions:  (a) PhSH, K2CO3, NMP, 150 °C, 57%  (b) 4-bromobutylphthalimide, 
K2CO3, DMF; (c) hydrazine; (d) Pierce ReactiGel (6x) 1,1-carbonyldiimadazole-activated 6% 
cross-linked beaded agarose (50 mol/ml) or Oregon Green carboxylic acid succinimidyl ester, 
K2CO3, DMF 
 
Scheme 10.  Synthesis of four-carbon linker modified KCN-1 and its derivatives 
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The KCN-1 linker coupled to agarose beads was used to pull down any interacting proteins 
in cell lysates.  One of the major components of the pull down experiments was a protein called 
plectin-1.  Plectin-1 is a large protein of approximately 500 kDa in size.  It acts as a link between 
the three major components of the cytoplasm: actin filaments, microtubules and intermediate 
filaments.85  As a result, plectin plays an important role in maintaining the mechanical strength 
and elasticity of tissues.86 
In order to investigate if there is a direct interaction between plectin-1 and KCN-1, the pro-
teins bound to the KCN-1 resin and the control resin was probed with plectin-1 antibody (BD 
bioscience) (Figure 4).  Plectin-1 was shown to bind to the KCN-1 affinity resin but not the con-
trol resin. 
                                    
Figure 8.  Gel electrophoresis of proteins from immobilized KCN1 and control matrix.  (This fig-
ure, courtesy of the Van Meir lab) 
 
Further studies into the mechanism of inhibition of KCN-1 on HIF-1, a comparison of the 
gene expression signatures of KCN1 and those of known Hsp90 inhibitors geldanamycin, 17-
AAG, and 17-DMAG were very similar.  Therefore, the possibility existed that KCN-1 could act 
via an identical mechanism.  To assess the binding of Hsp90 to KCN-1, the KCN-1 bound and 
the control matrices were incubated with the lysates of tumor cells, followed by the Western blot 
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analysis of the unbound and matrix-bound proteins. Hsp90 was undetectable in the eluates, 
suggesting that KCN-1 does not bind to the chaperone in cell extracts (Figure 5). 
 
                               
Figure 9.  Western blot analysis of the unbound and matrix-bound proteins.  (This figure, courte-
sy of the Van Meir lab) 
 
Based on these results and other experiments (not discussed here) by the Van Meir lab, 
it was hypothesized that KCN-1 may bind to plectin-1, but not to Hsp90.  A possible mechanism 
of action was suggested:  KCN-1 binds to plectin-1 and perturbs its 3-dimensional conformation.  
This plectin-1-KCN-1 complex binds to Hsp90 and traps it in the cytoplasm and therefore lowers 
its concentration in the nucleus.  As a result, Hsp90 is less available to HIF-1where it is needed 
to maintain its transcriptionally active conformation of HIF 
This initial hypothesis that KCN-1 binds to plectin-1 initiated some cell imaging experi-
ments to determine if KCN-1 did indeed bind to plectin.  KCN-1 was coupled to a green fluores-
cent dye - Oregon Green (Scheme 7) and used in fluorescent cell imaging studies. Oregon 
Green dye was chosen because it is not easily quenched and has a very bright green fluores-
cence as compared to its fluorescein counterpart.   The cells were also co-stained with plectin 
antibody (Texas Red) to see if any overlap would result.  The Oregon Green linked KCN-1 
(KCN-OG) was incubated with Hela cells (fixed with methanol) for 1 hour then washed to re-
move excess compound and observed under a fluorescent microscope.  The results showed the 
bright green color of KCN-OG in these cells (Figure 6A).   Under the confocal microscope, there 
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was indication that there may be significant overlap of the green KCN-OG and the Texas Red 
plectin antibody and therefore, they are perhaps binding to the same structure (Figure 6).  
In addition, we were able to obtain plectin-/- (plectin negative) mouse fibroblasts87 from 
the Van Meir lab to further explore the immunofluorescence experiments.  KCN-OG stained 
both the plectin -/- and the plectin +/+ cells.  These results indicated that the binding of KCN-OG 
may not be exclusive to plectin, but may bind to another cellular component as well (Figure 7). 
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Figure 10.  Fluorescent cell images of hela cells.  A. Cells labeled with KCN-OG. B. Plectin anti-
body (Texas Red). C. Overlap of A and B. (Confocal microscope × 100) 
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Figure 11.  Fluorescent cell images of mouse fibroblasts with KCN-OG and plectin antibody  A.  
Comparison of plectin positive cells B. Comparison of plectin negative cells. (Epifluorescent mi-
croscope × 25) 
 
Further probing into the mechanism by the Van Meir lab confirmed this result.  They ob-
served that although KCN-1 did indeed bind to plectin-1 it was not the main reason for the anti-
tumor activity of the compound.   Investigation into the components of the HIF-1 pathway re-
vealed that KCN-1 may be binding to the transcription co-factor p300.  More recently, the use of 
KCN-OG provided further clues about the interaction of KCN-1 with p300.  To explore the inte-
raction of KCN-1 with p300, the CH1 domain of p300 was amplified by PCR and cloned into a 
bacterial expression vector and GST/p300CH1 fusion protein was expressed.  
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Glutathione S-transferase (GST) binds to glutathione with very high affinity and GST fu-
sion proteins can be purified on immobilized glutathione (agarose beads coupled to glutathione).  
GST fusion proteins can then be mixed with various concentrations of KCN-OG and the fluores-
cence measured with a plate-reading fluorimeter (Stefan Kaluz – Emory University).   Figure 6A 
shows the binding of KCN-OG to 3 proteins:  GST only, GST galectin and GST-p300CH1.   
From this figure, it appears that KCN-OG binds the best to the p300.  In order to verify these 
results, a control compound of Oregon Green was prepared by blocking the amine reactive por-
tion of the Oregon green adduct with ethylamine.  As shown in Figure 6B, this Oregon green 
control showed almost no binding to p300, but KCN-OG did.  Therefore, it was concluded that 
the binding of KCN-OG to p300 was a result of KCN-1 and not the Oregon Green portion of the 
molecule. 
An additional experiment involved a competition assay with KCN-OG and EDTA, as well 
as KCN-OG and the known p300 CH1 inhibitor chetomin.  As previously stated in chapter 1.2, 
chetomin has been shown to be a disrupter of HIF binding to p300.  It works by disrupting the 
structure of the cysteine-histidine-rich domain 1(CH1) domain of p300 and interferes with its in-
teraction with HIF.  Therefore, HIF-1 transcription is inhibited.70  Chetomin reacts with p300, 
causing zinc ion ejection.71   EDTA has been shown to chelate to the zinc ions coordinated by 
CH1 and disrupt its structure.88  Therefore, competition experiments with EDTA (Figure 10A) 
and chetomin (Figure 10B) were conducted.  In both cases, KCN-OG was used at 20 M.  It 
seems evident from this experiment that even in the presence of vast excess of EDTA and a 
moderate concentration of chetomin there is still significant KCN-OG binding.  This result shows 
that KCN-OG does not act in the same way or at the same point on the CH1 domain as cheto-
min or EDTA.  This result is not surprising, since the structure of KCN-1 does not in any way 
indicate that it can bind to zinc and disrupt the CH1 domain of p300.   
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Figure 12.  Binding of KCN-1-OG to GST-proteins (This figure, courtesy of the Van Meir lab) 
 
Figure 13.  Binding of KCN-1-OG and OG control to GST-p300CH1 (This figure, courtesy of the 
Van Meir lab) 
 
46 
 
 
Figure 14.  Binding of KCN-OG to GST-p300CH1.  (This figure, courtesy of the Van Meir lab)  
 
       Summary of mechanistic studies 
KCN-1 modified with a 4-carbon linker with a terminal amine was used to couple to agarose 
beads as well as an Oregon Green fluorophore.  These compounds have provided important 
clues into the mechanism of action of KCN-1, especially as it related to its binding to the tran-
scriptional co-activator, p300. Further experiments will be necessary to verify that binding of 
KCN-1 to p300 is responsible for the inhibitory and anti-tumor activity of KCN-1.   
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4 CONCLUSIONS AND FUTURE OUTLOOK 
 
Several potent analogues of KCN-1 were synthesized.  Many of these compounds have ac-
tivity against HIF-1 in the submicromolar range.  The best analogues were the pyra-
no(3,2b)pyridines, of which compound 26i was the best overall compound with an IC50 of 0.25 
M.  The benzofuran derivatives also showed good potential, especially since they were void of 
the alkene that is present in the KCN-1 molecule. 
The analogues synthesized allowed for an understanding of the structure- activity relation-
ship profile of KCN-1:   A sulfonamide or amide group is preferred at Region I of KCN-1.  Also, 
alkyl rings of 4 or 5 carbons are preferred in Region II of KCN-1.  Aromatic rings are preferred in 
Region III and cyclohexyl rings are also tolerated.  The pyrano(3,2b)pyridines were best in Re-
gion IV of KCN-1.  More potent analogues can be generated in the future, that take all of these 
structural features into consideration.   
KCN-1 modified with the 4-carbon linker and attached to either a fluorophore or agarose 
beads was very useful in understanding the anti-tumor mechanism of KCN-1.  Since p300 is 
now being investigated as the possible binding partner for KCN-1, molecular modeling studies 
of this interaction will be very useful in generating more potent analogues.  Molecular modeling 
studies can take advantage of interaction between KCN-1 and the p300 protein that are impor-
tant for activity. 
These HIF-1 inhibitors have good potential to be drug candidates for the treatment of can-
cer.  These compounds have the potential to be especially effective in tumors that are resistant 
to chemotherapeutic and radiation therapies because of hypoxia.  Combination therapy of KCN-
1 analogues, together with chemotherapeutic drugs already in use may produce the best re-
sults. 
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5 EXPERIMENTAL 
 
5.1 Biology 
 
HRE-Luciferase assay.  The Inhibition constants (IC50), the inhibitor concentration that produc-
es 50% inhibition in the presence of substrate [S] was determined in the laboratory of Dr. Erwin 
Van Meir of Emory University.  LN229-HRE-luciferase glioblastoma cell was stably integrated 
with a reporter construct made of 6 copies of the HIF responsive element derived from the 
VEGF gene cloned in front of a luciferase gene.  The cells were treated with drugs of choice 
(KCN1 or analogs) for 1 hour, and then transferred to a hypoxia incubator (1% hypoxia) and 24 
hours later the luciferase activity measured. 
 
Expression and purification of glutathione-S-transferase (GST)/p300CH1 fusion protein.  
CH1 domain of p300 was amplified by PCR and cloned in frame into a pGEX-2T vector (bac-
terial expression vector). This construct, upon induction with 0.1 M IPTG for 4 hrs, expressed 
GST/p300CH1 fusion protein.  GST fusion proteins were purified on immobilized glutathione 
(agarose beads coupled to glutathione). This procedure typically yields 95-100% pure GST fu-
sion protein. 
KCN-OG binding assay.  GST fusion proteins (approx. 3 g, still on immobilized glutathione) 
were mixed with various concentrations of KCN-OG in 1 ml of Dulbecco’s Phosphate Buffered 
Saline (DPBS), rocked overnight at 4° C.  Tubes were centrifuged for 5 seconds, supernatant 
carefully removed, and the beads were washed 3 times with 1 ml of DPBS (simple inverting 5-
10x, centrifugation 5s). Beads with bound KCN-OG were mixed with elution buffer (120 l, 10 
mM dithiothreitol), boiled at 100 °C for 10 min, centrifuged 5s, and supernatants was transferred 
into a 96-well plate and the fluorescence was measured in plate-reading fluorimeter. Competi-
49 
 
tion with EDTA, chetomin, or KCN1 was performed similarly, except for the pre-treatment of 
GST proteins with these agents for 1 hour, when KCN-OG was added. 
5.2 Chemistry 
All reagents were purchased from Acros, Aldrich and Matrix Scientific and were used as re-
ceived without further purification.  Microwave heating was performed in a single-mode micro-
wave cavity of a Discover Synthesis System (CEM corp.) and all microwave-irradiated reactions 
were conducted in a heavy walled glass vials sealed with Teflon septa.  1H NMR and 13C NMR 
were recorded at 400 MHz on a Bruker 400 NMR spectrometer.  Mass Spectra was performed 
by the mass spectrometry facilities at Georgia State University.  
  
General procedure for reductive amination for synthesis of 2a - 2f 
To a solution of 2,2-dimethyl-2H-chromene-6-carbaldehyde 1 (1 eq) in methanol was added the 
amine (2 eq), sodium cyanoborohydride (2 eq) and zinc chloride (dried) (2 eq.).  The reaction 
was stirred overnight. Then the solvent was removed by rotary evaporation and a 1M NaOH so-
lution was added to the residue.  The organic layer was extracted with ethyl acetate or DCM (× 
2), dried over magnesium sulfate and concentrated in vacuo.  The compound was purified by 
flash column chromatography. 
 
(3,4-Dimethoxy-phenyl)-(2,2-dimethyl-2H-chromen-6-ylmethyl)-amine (2a).  Yield: 60%.  1H 
NMR (CDCl3): δ 7.09 (dd, J = 8.2, 2.1 Hz, 1H), 6.99 (d, J = 2.0 Hz, 1H), 6.74 (d, J = 8.4 Hz, 2H), 
6.30 (s, 1H), 6.30 – 6.24 (m, 1H), 6.17 (dd, J = 8.5, 2.6 Hz, 1H), 5.61 (d, J = 9.8 Hz, 1H), 4.15 (s, 
2H), 3.81 (t, J = 6.2 Hz, 6H), 1.43 (s, 6H).  13C NMR (CDCl3): δ 152.2, 150.0, 143.3, 141.6, 
131.6, 131.0, 128.4, 125.7, 122.2, 121.3, 116.4, 113.3, 103.6, 99.0, 76.2, 56.7, 55.7, 48.8, 28.0.  
HRMS (ESI +): C20H23NO3 + H: observed: 326.1750, calculated: 326.1756. 
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(2,2-Dimethyl-2H-chromen-6-ylmethyl)-methyl-pyridin-2-yl-amine (2b).  Yield: 60%.  1H 
NMR (CDCl3):   8.10 - 8.08 (m, 1H), 7.77- 7.35 (m, 1H), 7.08 – 7.07 (m, 1H), 7.00 – 6.96 (m, 
1H), 6.77 – 6.72 (m, 1H), 6.50 – 6.58 (m, 1H), 6.36 (d, J = 8.4 Hz, 1H), 6.28 (d, J = 9.6 Hz, 1H), 
4.80 (s, br,1H), 4.40 (s, 2H), 1.41(s, 1H). HRMS (ESI+): C17H18N2O + H: observed: 267.1505, 
calculated: 267.1497.  
 
 (2,2-Dimethyl-2H-chromen-6-ylmethyl)-(2,4-dimethyl-phenyl)-amine (2c).  Yield: 69%.   1H 
NMR (CDCl3):  7.10 (dd, J = 6.0 Hz, 2.4 Hz, 1H), 6.99 (d, J = 8.0 Hz), 6.92 – 6.90 (m, 1H), 6.74 
(d, J = 8.4 Hz, 1H), 6.54 (d, J = 7.6 Hz,1H), 6.30 (d, J = 9.6 Hz, 1H) 4.21 (s, 2H), 2.23 (s, 3H), 
2.12 (s, 3H), 1.43 (s, 6H). MS (ESI+): M + H = 292. 
 
 4-[(2,2-Dimethyl-2H-chromen-6-ylmethyl)-amino]-benzoicacid (2d).  1H NMR ((CD3)2SO):  
1.35 (s, 6H), 4.17 (d, J = 5.5 Hz, 2H), 5.72 (d, J = 9.8 Hz, 1H), 6.37 (d, J = 9.8 Hz, 1H), 6.54 (d, 
J = 7.7 Hz, 2H), 6.68 (d, J = 8.2 Hz, 1H), 7.03 (s, 1H) ,7.08 (s, 1H), 7.71 (s, 2H).  HRMS (ESI -): 
C19H19NO3  - H: observed: 308.1276, calculated: 308.1287. 
 
(2-Bromo-phenyl)-(2,2-dimethyl-2H-chromen-6-ylmethyl)-amine (2e). Yield: 11%. 1H NMR 
(CDCl3)  7.43 (d, J = 7.8 Hz, 1H), 7.20 – 7.04 (m, 2H), 6.97 (s, 1H), 6.75 (d, J = 8.2 Hz, 1H), 
6.62 (d, J = 8.0 Hz, 1H), 6.58 (d, J = 7.1 Hz, 1H), 6.30 (d, J = 9.8 Hz, 1H), 5.61 (d, J = 9.8 Hz, 
1H), 4.63 (s, 1H), 4.26 (d, J = 5.3 Hz, 2H), 1.43 (s, 6H).13C NMR (CDCl3)  152.3, 144.9, 132.4, 
131.1, 130.7, 128.1, 125.4, 122.2, 121.4, 117.9, 116.5, 111.6, 109.6, 76.3, 47.6, 28.0.  HRMS 
(ESI +): C18H18NOBr + H: observed: 344.0663, calculated: 344.0650. 
 
(2,2-Dimethyl-2H-chromen-6-ylmethyl)-(2-fluoro-phenyl)-amine (2f). Yield: 71%. 1H NMR 
(CDCl3):  7.10 (dd, J = 6.0, 2.0 Hz, 1H), 6.99 – 6.94 (m, 3H), 6.76 – 6.56 (m, 3H), 6.29 (d, J = 
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9.6 Hz, 1H), 5.61 (d, J = 9.6Hz, 1H), 4.23 (s, 3H), 1.43 (s, 6H).   13C NMR (CDCl3): 152.4, 143.9, 
138.1, 136.3, 130.9, 128.3, 128.2, 127.5, 127.1, 124.7, 123.5, 122.3, 121.1, 116.2, 77.3, 28.1, 
21.5.  HRMS (ESI +):  C18H18NOF + H: observed: 284.1442, calculated: 284.1451. 
General Procedure for synthesis of 3a - 3c by methylation of secondary amines 2a, 2b 
and 2c, respectively.  To a solution of secondary amine 2 (1 eq) in THF was added to a flask 
containing NaH (2 eq) in THF. After 5 minutes, MeI (2 eq) was added and the reaction allowed 
to stir overnight. The reaction mixture is quenched with water and diluted with ethyl acetate.  
The organic layer was washed with water and brine, dried over MgSO4 and concentrated in va-
cuo.  
(3,4-Dimethoxy-phenyl)-(2,2-dimethyl-2H-chromen-6-ylmethyl)-methyl-amine (3a).  1H 
NMR (CDCl3)  6.98 (dt, J = 7.2, 3.6 Hz, 1H), 6.87 (s, 1H), 6.78 (d, J = 8.7 Hz, 1H), 6.73 (s, 1H), 
6.43 (s, 1H), 6.27 (d, J = 10.1 Hz, 2H), 5.59 (d, J = 9.8 Hz, 1H), 4.31 (s, 2H), 3.82 (d, J = 2.2 Hz, 
6H), 2.89 (s, 3H), 1.42 (s, 6H).  13C NMR (CDCl3)  149.7, 145.6, 131.2, 130.9, 127.9, 125.1, 
122.3, 121.3, 116.3, 113.0, 104.8, 99.5, 77.4, 77.0, 76.7, 76.2, 57.6, 56.7, 55.8, 38.9, 28.0.  
HRMS (ESI +): C21H25NO3 +H: observed: 340.1900, calculated: 340.1913. 
(2,2-Dimethyl-2H-chromen-6-ylmethyl)-methyl-pyridin-2-yl-amine (3b).  1H NMR (CDCl3)   
8.21 (m, 1H), 7.45 (m, 1H), 6.99 (d, J = 8.5 Hz, 1H), 6.86 (s, 1H), 6.72 (d, J = 8.0 Hz, 1H), 6.52-
6.59 (m, 2H), 6.28 (d, J = 10Hz, 1H), 5.60 (d, J = 10 Hz, 1H), 4.70 (s, 2H), 3.06 (s, 3H), 1.44 (s, 
6H).  13C NMR (CDCl3)  151.9, 148.0, 137.2, 130.9, 130.8, 127.8, 125.0, 122.4, 121.3, 116.3, 
11.7, 105.8, 76.1, 52.6, 36.0, 28.0.  HRMS (ESI +): C18H20N2O3 + H observed: 281.1659, calcu-
lated: 281.1654. 
 
(2,2-Dimethyl-2H-chromen-6-ylmethyl)-(2,4-dimethyl-phenyl)-methyl-amine(3c).  Yield: 
48%.  1H NMR (CDCl3) d 7.13 (dd, J = 2.0, 6.0 Hz, 1H), 7.05 – 7.00 (m, 4H), 6.75 (d, J = 8.0 Hz, 
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1H), 6.34 (d, J = 9.6 Hz, 1H), 5.63 (d, J = 9.2 Hz, 1H), 3.88 (s, 2H), 2.55 (s, 3H), 2,40 (s, 3H), 
2.31 (s, 3H), 1.45 (s, 6H). MS (ESI+): M + H = 308. 
 
N-Benzyl(2,2-dimethyl-2H-chromen-6-yl)methanamine (4q).  Follows general procedure for 
reductive amination as for  compound 2 using benzylamine.  1H NMR (CDCl3): 7.37 -7.36 (m, 
5H), 7.10 (d, J =2.0 Hz, 1H), 6.77 (d, J = 9.0 Hz, 1H), 6.34 (d, J = 9.6 Hz, 1H), 5.63 (d, J = 9.6 
Hz, 1H), 3.84 (s, 1H), 3.73 (s, 1H), 1.46 (s, 6H). 
 
General Procedure for synthesis of 5a –5r by alkyl sulfonation.  To a solution of the sec-
ondary amine 4 (1 eq) in dichloromethane was added triethylamine (3 eq) and sulfonylchloride 
(1.5 eq), the reaction was allowed to stir for 24 to 48 hours, then water was added and the or-
ganic layer extracted with dichloromethane, dried over magnesium sulfate and concentrated in 
vacuo and purified by flash column chromatography. 
 
N-(2,2-Dimethyl-2H-chromen-6-ylmethyl)-N-isopropyl-3,4-dimethoxy-benzenesulfonamide 
(5a). Yield: 58%.  1H NMR (CDCl3)  7.39 (dd, J = 6.4, 2.0 Hz, 1H), 7.22 (d, J = 2.0 Hz, 1H), 
7.07 (dd, J = 6.0, 2.0 Hz, 1H), 7.00 (d, J = 2.0 Hz, 1H), 6.90 (t, J = 8.6 Hz, 1H), 6.69 (d, J = 8.2 
Hz, 1H), 6.28 (d, J = 9.8 Hz, 1H), 5.60 (d, J = 9.8 Hz, 1H), 4.39 – 4.19 (m, 2H), 4.23 – 4.02 (m, 
1H), 4.04 – 3.73 (m, 6H), 1.41 (s, 6H), 1.05 (d J = 7.2 Hz, 6H).  13C NMR (CDCl3):  152.2, 
152.2, 149.0, 133.2, 131.0, 130.8, 128.6, 126.0, 122.3, 121.2, 120.8, 116.1, 110.5, 109.6, 76.34, 
56.2, 56.1, 50.0, 46.0, 27.9, 21.3.  HRMS (ESI +): C23H29NO5S + Na   observed: 451.1651 Calc: 
451.1664.  
 
N-(2,2-Dimethyl-2H-chromen-6-ylmethyl)-3,4-dimethoxy-N-prop-2-ynyl-
benzenesulfonamide (5b). Yield: 95%.  7.53 (dd, J = 2.0 Hz, 1H), 7.38 (d, J = 2.0 Hz, 1H), 7.09 
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– 7.07 (m, 1H), 7.00 – 6.96 (m, 2H), 6.74 (d, J = 8.0 Hz, 1H), 6.31 (d, J = 9.6 Hz, 1H), 5.64 (d, J 
= 9.6 Hz, 1H), 4.24 (s, 1H), 4.01 – 3.96 (m, 7 H), 1.59 (s, 2H), 1.43 (s, 6H).  HRMS (ESI +): 
C23H25NO5S + Na: observed: 450.1352, calc: 450.1351.  
 
(N-Butyl-N-(2,2-dimethyl-2H-chromen-6-ylmethyl)-3,4-dimethoxy-benzenesulfonamide 
(5c). Yield: 55%. 1H NMR (CDCl3):  7.46 (dd, J = 6.4, 2.1 Hz, 1H), 7.28 (m, 1H), 7.00 – 6.89 (m, 
2H), 6.71 (d, J = 8.0 Hz, 1H), 6.27 (d, J = 10.0 Hz, 1H), 5.63 (d, J = 9.6 Hz, 1H), 4.23 (s, 1H), 
3.97 – 3.92 (m, 6H), 3.10 (t, J = 7.6 Hz, 2H), 1.43(s, 6H), 1.38 – 1.16 (m, 6H), 0.79 (t, J = 7.6 Hz, 
3H). 13C NMR (CDCl3): 152.3, 149.0, 132.2, 131.1, 129.1, 128.5, 126.4, 122.1, 121.3, 121.0, 
116.2, 110.5, 109.8, 76.3, 56.2, 56.2, 51.1, 47.4, 30.0, 27.9, 19.8, 13.6.  HRMS (ESI +): 
C24H31NO5S + Na: observed: 468.1815, calculated: 468.1821. 
 
(N-tert-Butyl-N-(2,2-dimethyl-2H-chromen-6-ylmethyl)-3,4-dimethoxy-benzenesulfonamide 
(5d). Yield: 49%.  1H NMR (CDCl3)  7.41 (dd, J = 8.5, 2.1 Hz, 1H), 7.22 – 7.12 (m, 2H), 7.06 (d, 
J = 2.1 Hz, 1H), 6.87 (d, J = 8.5 Hz, 1H), 6.74 (t, J = 9.7 Hz, 1H), 6.30 (t, J = 8.9 Hz, 1H), 5.62 (t, 
J = 9.5 Hz, 1H), 4.56 (s, 2H), 3.94 (d, J = 13.4 Hz, 3H), 3.85 (d, J = 14.6 Hz, 3H), 1.48 – 1.39 (m, 
6H), 1.33 (s, 9H).  
 
(N-Allyl-N-(2,2-dimethyl-2H-chromen-6-ylmethyl)-3,4-dimethoxy-benzenesulfonamide (5e). 
Yield: 53%.  1H NMR (CDCl3)  7.48 (dd, J = 8.4, 2.2 Hz, 1H), 7.29 (t, J = 2.3 Hz, 1H), 7.01 – 
6.91 (m, 2H), 6.88 (d, J = 2.1 Hz, 1H), 6.72 (t, J = 9.7 Hz, 1H), 6.29 (d, J = 6.4 Hz, 1H), 5.64 (t, J 
= 10.6 Hz, 1H), 5.53 (ddt, J = 16.7, 10.2, 6.5 Hz, 1H), 5.09 (ddd, J = 18.4, 13.6, 1.3 Hz, 2H), 
4.28 (d, J = 25.4 Hz, 2H), 4.03 – 3.95 (m, 3H), 3.95 – 3.88 (m, 3H), 3.84 – 3.72 (m, 2H), 1.44 (s, 
6H).  13C NMR (CDCl3):  152.6, 152.4, 149.1, 132.4, 132.4, 131.9, 129.4, 127.9, 126.6, 122.1, 
121.3, 121.1, 199.2, 116.2, 110.6, 109.8, 76.4, 56.2, 56.2, 49.6, 49.2, 28.0. EI probe: M + = 429. 
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HRMS (ESI +): C23H27NO5 + Na, observed: 452.1505, calculated.: 452.1508. 
 
Pyridine-2-sulfonic acid (2,2-dimethyl-2H-chromen-6-ylmethyl)-isopropyl-amide (5f).  1H 
NMR (CDCl3):  d 8.33 (d, J = 4.8, 1H), 7.69 – 7.61 (m, 1H), 7.50 (dd. J = 1.2, 7.2 Hz, 1H), 7.34 
(dd, J= 2.4, 6.4 Hz, 1H), 7.27 -7.00 (m, 3 H), 6.97 (d, J = 2.0 Hz, 1H), 6.90 (d, J = 8.4 Hz, 1H), 
6.24 (d, J = 8.0 Hz, 1H), 5.57 (d, J = 10 Hz, 1H), 4.87 (s, 2H), 3.95 (s, 3H), 3.77 (s, 3H), 1.59 (s, 
6 H).  ESI (+): M+H = 467. 
 
 (N-(2,2-Dimethyl-2H-chromen-6-ylmethyl)-3,4-dimethoxy-N-(3-methyl-butyl)-
benzenesulfonamide (5g). Yield: 31%.  1H NMR (CDCl3): 7.44 (dd, J = 6.4, 2.0 Hz), 7.29 – 
7.28 ( m, 1H), 6.96 – 6.94 (m, 2H), 6.83 (s, 1H), 6.24 (d, J = 10.0 Hz, 1H), 5.62 (d, J = 10.0 Hz, 
1H), 3.97 – 3.92 (m, 6H), 2.90 (d, J = 7.6 Hz, 2H), 1.75 (sep, J = 6.8 Hz, 1H), 1.43 (s, 6H), 0.792 
– 0.779 (m, 6H).  13C NMR (CDCl3):   152.5, 152.2, 149.0, 132.1, 131.1, 129.2, 128.5, 126.5, 
122.1, 121.1, 116.1, 110.5, 109.9, 76.3, 56.2, 56.2, 55.8, 52.1, 27.9, 26.8, 20.0. HRMS (ESI +): 
C24H31NO5S + Na: observed: 468.1801, calculated: 468.1821. 
 
(N-Cyclopentyl-N-(2,2-dimethyl-2H-chromen-6-ylmethyl)-3,4-dimethoxy-
benzenesulfonamide (5h). Yield: 58%. 1H NMR (CDCl3) δ 7.39 (d, J = 6.4 Hz, 1H), 7.21 (d, J = 
2.1 Hz, 1H), 7.10 – 6.82 (m, 3H), 6.67 (d, J = 8.2 Hz, 1H), 6.26 (d, J = 9.8 Hz, 1H), 5.57 (d, J = 
9.8 Hz, 1H), 4.22 (s, 3H), 3.88 (d, J = 20.2 Hz, 6H), 1.70 – 1.18 (m, 15H).  13C NMR (CDCl3):   
152.2, 152.1, 149.0, 132.7, 131.0, 130.9, 127.9, 152.3, 122.3, 121.2, 121.0, 116.1, 110.5, 109.9, 
76.2, 59.5, 56.2, 56.1, 46.8, 29.3, 28.0, 23.5.  HRMS (ESI +): C25H31NO5S + Na: observed: 
480.1822, calculated: 480.1832 
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Cyclopropyl-N-(2,2-dimethyl-2H-chromen-6-ylmethyl)-3,4-dimethoxy-benzenesulfonamide 
(5i). Yield: 47%.  1H NMR (CDCl3):  7.46(dd, J = 2.0, 6.4 Hz, 1H), 7.27(d, J = 2.0Hz, 1H), 7.06 
(dd, J = 2.0, 6.4 Hz, 1H), 6.97- 6.93 (m, 2H), 6.70 (d, J = 8.0 Hz, 1H), 6.29 (d, J = 9.6 Hz, 1H), 
4.27 (s, 2H), 5.62 (d, J = 9.6 Hz, 1H),  2.01(quin, J = 4.0, 1H), 1.44( s, 6H), 0.720 (q, J = 3.2 Hz, 
2H), 0.591(q, J = 3.2 Hz, 2H).  13C NMR (CDCl3)  152.5, 148.9, 131.0, 130.5, 129.7, 129.0, 
126.9, 122.2, 121.6, 121.1, 116.0, 110.4, 110.2, 76.3, 56.2, 56.2, 54.2, 30.6, 28.0, 7.3.  HRMS 
(ESI +): C23H27NO5S + Na: observed: 452.1489, calculated: 452.1508 
 
N-Cyclohexyl-N-(2,2-dimethyl-2H-chromen-6-ylmethyl)-3,4-dimethoxy-
benzenesulfonamide (5j).  Yield: 79%.  1H NMR:  7.42 (dd, J = 2.0 Hz, 6.4 Hz, 1H), 7.30 – 
7.15 (m, 1H), 7.16 (d, J = 8.4 Hz, 1H), 7.10 – 7.08 (m, 1H), 7.02 (d, J = 2.0 Hz, 1H), 6.91 (d, J = 
8.4 Hz, 1H), 6.71 (d, J = 8.0 Hz, 1H), 6.31 (d, J = 9.6 Hz, 1H), 5.63 (d, J = 9.6 Hz, 1H), 4.31 (s, 
2H), 3.95 (s, 3H), 3.90 (s, 3H), 1.70 – 1.54 (m, 4H), 1.43 (s, 6H), 1.27 – 1.20 (m, 6H).  Yield: 
79%.  HRMS (ESI+): C26H33NO5S + Na: observed: 494.1998, calculated: 44.1977. 
 
General Procedure for synthesis of 5k - 5p 
To a solution of secondary amine 4 (1 eq) in DCM was added triethylamine (3 eq), then appro-
priate sulfonylchloride (2 eq).  The reaction was allowed to stir at room temperature for 24 hours 
after which sat. NH4Cl was added to the reaction mixture and extracted with DCM (× 2), dried 
over MgSO4 and concentrated under vacuum.  The crude product was purified by flash column 
chromatography.  
 
N-((2,2-Dimethyl-2H-chromen-6-yl)methyl)-4-methoxy-N-phenylbenzenesulfonamide (5k).  
Yield: 30 %.  1H NMR (CDCl3):   7.60 (d, J = 9.2 Hz, 1H), 7.28-7.22 (m, 3H), 7.00 – 6.90 (m, 
4H), 6.62 (d, J =9.2 Hz, 1H), 6.24 (d, J = 10.0 Hz, 1H), 5.58  (d, J = 10 Hz, 1H), 4.62 (s, 2H), 
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3.90 (s, 3H), 1.40 (s, 6H).  13C NMR: 162.90, 139.1, 130.9, 129.8, 129.3, 129.1, 128.8, 128.1, 
127.6, 126.6, 122.3, 116.0, 114.0, 76.3, 55.6, 54.3, 28.0. MS: ESI (+): M + Na = 458 
 
N-((2,2-Dimethyl-2H-chromen-6-yl)methyl)-3,5-dimethyl-N-phenylbenzenesulfonamide (5l). 
1H NMR:  7.54 (s, 2H), 7.30 – 7.23 (m, 3H), 7.00 – 6.97 (m, 1H), 6.90 – 6.88 (m, 2H), 6.60 (d, J 
= 8.8 Hz, 1H), 6.24 (d, J = 10 Hz, 1H), 5.58 (d, J = 9.6 Hz, 1H), 4.63 (s, 2H), 2.41 (s, 3H), 2.36 
(s, 3H), 1.42 (s, 6H).  
 
2,5-Dichloro-N-((2,2-dimethyl-2H-chromen-6-yl)methyl)-N-phenylbenzenesulfonamide  
(5m).  Yield: 23%.  1H NMR (CDCl3):  7.84 (d, J = 2.4 Hz, 1H), 7.48 (d, J = 8.4 Hz, 1H), 7.44 – 
7.40 (m, 1H), 7.23 – 7.21 (m, 3H), 7.06 – 7.04 (m , 2H), 6.92 – 6.90 (m, 2H), 6.64 (d, J = 7.6 Hz, 
1H), 6.27 (d, J = 10.0 Hz, 1H), 5.60 (d, J = 9.6 Hz, 1H), 4.92 (s, 2H), 1.42 (s, 6H).   
 
4-Bromo-N-((2,2-dimethyl-2H-chromen-6-yl)methyl)-N-phenyl-2-
(trifluoromethoxy)benzenesulfonamide (5n).  Yield: 23 %.  1H NMR (CDCl3):   1.45 (s, 6H), 
4.95 (s, 2H), 5.60 (d, 1H, J = 9.6), 6.27 (d, 1H, J = 10), 6.64 (s, 1H, J = 7.6), 6.91 (m, 2H), 7.05 
(m, 2H), 7.21 (m, 3H,) 7.43 (m, 1H) 7.48 (m, 1H), 7.84 (d, 1H, 2.4).  
 
4-(3-Ethylpent-1-yn-3-yloxy)benzaldehyde (7).  To a solution of 3-methyl-1-pentyn-3-ol 6 
(0.319 mL, 2.83 mmol) in acetonitrile (3ml) at 0oC was added DBU (0.55 mL, 3.69 mmol). Then, 
TFAA (0.34 mL, 2.46 mmol) was added drop wise and stirred at 0°C for 30 minutes.  To a solu-
tion of 4- hydroxybenzaldehyde (300 mg, 2.46 mmol) in acetonitrile at 0oC was added DBU 
(0.55 mL, 3.69 mmol) and CuCl2.2H2O (0.42 mg, 0.0025 mmol).  The first mixture was added to 
the second mixture over a period of five minutes.  The reaction was stirred overnight.  The sol-
vent was removed by rotary evaporation and the residue diluted with DCM and the organic layer 
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washed with 1M HCl, 1M NaOH, sat NaHCO3 and brine.  The organic layer was dried over 
MgSO4 and concentrated in vacuo to give 170 mg (32%) of product as a brown oil . 1H NMR 
(CDCl3): d 9.91(s, 1H), 7.83 – 7.81 (m, 2H), 7.36 -7.34 (m, 2H), 2.69 (s, 1H), 2.06 – 1.92 (m, 2H), 
1.66 (s, 3H), 1.12 (t, J = 7.2 Hz, 3H).  
 
2-Ethyl-methyl-2H-chromene-6-carbaldehyde (8).  A solution of 7 (170 mg) in xylene (3 mL) 
was subjected to microwave irradiation for 100 minutes at 220 W, 200 torr, 120 oC.  The solvent 
was removed in vacuo to give a quantitative yield of product (170 mg).  1H NMR(CDCl3): 9.81 
(s, 1H), 7.63 (dd, J = 8.0 Hz, 2.0 Hz, 1H), 7.50 (d, J = 2.0 Hz, 1H), 6.85 (d, J = 8.4 Hz, 1H), 6.42 
(d, J = 10.0 Hz, 1H), 5.62 (d, J = 10.0 Hz, 1H), 1.81 – 1.66 (m, 3H), 1.43 (s, 3H), 0.97 (t, J = 7.6 
Hz, 3H).  
 
N-((2-Ethyl-2-methyl-2H-chromen-6-yl)methyl)benzenamine (9).  Reaction was carried out 
with the same procedure as for 2a - 2f using 170 mg of 8 to give 90.9 mg (41%) of product. 
1HNMR (CDCl3):  7.22- 7.18 (m, 5H), 7.11(dd, J = 6.0 Hz, 2.4 Hz, 1H), 6.99 (d, J = 2.0 Hz, 2H), 
6.77 -6.74 (m, 3H), 6.68 – 6.66 (m, 2H), 6.36 (d, J = 10.0 Hz, 1H), 5.58 (d, J = 10.0 Hz, 1H), 
4.21 (s, 2H), 1.76 – 1.71 (m, 3H), 1.33(s, 3H), 0.96 (t, J = 7.6 Hz, 3H).  
 
N-((2-Ethyl-2-methyl-2H-chromen-6-yl)methyl)-3,4-dimethoxy-N-
phenylbenzenesulfonamide (10).  To a solution of 9 (80 mg, 0.29 mmol) in DCM (3mL) was 
added Et3N (0.12 ml, 0.85 mmol) and 3,4-dimethoxybenzenesulfonyl chloride (135mg, 0.573 
mmol).  After 24 hours, sat.NH4Cl was added to the reaction mixture and the aqueous layer was 
extracted with DCM (5 × 2 ml), dried over MgSO4 and concentrated under vacuum.  The crude 
product was purified by column (silica gel, 5: 1 Hx/EtOAc) to give a white solid. 1H NMR(CDCl3): 
 7.35 (dd, J = 6.4 Hz, 2.0 Hz, 1H), 7.25 – 7.23 (m , 3H), 7.02 – 6.98 (m, 3H), 6.94 (d, J = 8.4 Hz, 
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1H), 6.91 – 6.88 (m, 2H), 4.62 (s, 2H), 3.98 (s, 3H), 3.77 (s, 3H), 1.71 – 1.65 (m, 2H), 1.43 (s, 
3H), 0.94 (t, J = 7.6 Hz, 3H).  13C NMR (CDCl3): 152.8, 152.5, 148.7, 139.2, 130.5, 129.8, 
129.3, 129.2, 128.8, 127.9, 127.8, 126.6, 122.8, 121.4, 121.1, 115.8, 110.4, 79.0, 56.2, 56.1, 
54.3, 34.0, 26.0, 8.2. MS (ESI +): M + Na = 502 
 
N-Phenylquinolin-3-amine (12).  To a solution of quinoline-3-carbaldehyde 11 (79 mg, 0.5 
mmol) in MeOH (5mL) was added aniline (0.05 mL, 0.55 mmol) and ZnCl2 (136 mg, 2.0 mmol) 
and allowed to stir at room temperature for 15 minutes.  Then, NaCNBH3 (62.84 mg, 2.0 mmol) 
was added and allowed to stir overnight at room temperature. The solvent was removed by rota-
ry evaporation and the residue suspended in EtOAc.  The organic layers were washed with 
NaHCO3, water and brine and the combined organic layers were dried over MgSO4 and concen-
trated in vacuo.  The crude product was used in the next step without further purification. 1H 
NMR (CDCl3): 9.05 (s, 1H), 8.23 (d,  J = 7.6 Hz, 2H), 7.77 (d, J = 8.0 Hz, 1H), 7.71 – 7.66 (m, 
1H), 7.54 – 7.51 (m, 1H), 7.21 – 7.16 (m, 2H), 6.76 – 6.72 (m, 1H), 6.68 – 6.60 (m, 2H), 4.54 (s, 
2H), 4.16 (s, br, 1H). 
 
3,4-Dimethoxy-N-phenyl-N-(quinolin-3-ylmethyl)benzenesulfonamide (13).  To a solution of 
12 (75 mg, 0.320 mmol) in DCM was added 3,4 dimethoxy benzylsulfonyl chloride (83mg, 0.35 
mmol) and triethylamine( 0.09 ml, 0.640 mmol). The reaction was allowed to stir overnight at 
room temperature and the reaction mixture was washed with water and brine and the combined 
organic layers were dried over MgSO4 and concentrated in vacuo. Purified by column chroma-
tography: silica gel, 2:1 Hexane/EtOAc to give a white powder. 1H NMR(CDCl3): 8.86 (s, 1H), 
8.14(d, J = 8.0 Hz, 2H), 7.84 (dd, J =7.2 Hz, 1.2 Hz, 1H), 7.80 – 7.76 (m, 1H), 7.64 -7.60 (m, 
1H), 7.49 (dd, J = 6.0 Hz, 2.4 Hz, 1H), 7.38 – 7.30 (m, 3H), 7.17 – 7.14 (m, 2H), 7.08 – 7.05 (m, 
2H), 5.03 (s, 2H), 4.08 (s, 3H), 3.85 (s, 3H). 13C NMR (CDCl3): 152.8, 150.8, 148.8, 147.6, 138.7, 
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135.7, 129.6, 129.2, 129.1, 129.0, 128.2, 127.7, 127.7, 126.9, 121.6, 110.5, 110.4, 56.2, 56.1, 
52.4.  MS (ESI+): M + H = 435. 
 
N-((2,2-Dimethyl-2H-chromen-6-yl)methyl)benzenamine (15a).  To a solution of 2,3-Dihydro-
2,2-dimethylbenzofuran-5-carboxaldehyde 14 (250 mg, 1.42 mmol) in MeOH(10ml) was added 
aniline (0.14 ml, 1.022 mmol), NaCNBH3 (178 mg, 2.84 mmol) and ZnCl2 (dried in oven) (387mg, 
2.84 mmol).  The reaction was allowed to stir at room temperature overnight, and then the sol-
vent was removed by rotary evaporation.  0.1M NaOH was added to the resulting residue and 
extracted with EtOAc (× 2), dried over MgSO4 and concentrated in vacuo to give 301 mg of 
product (84 %).  1H NMR (CDCl3): d 7.29 – 7.22 (m, 3H), 7.17 (d, J = 8.0 Hz,1H), 6.95 – 6.70 (m, 
4H), 4.28 (s, 2H), 3.06 (s, 2H), 1.55 (s, 6H).  
 
N-((2,2-Dimethyl-2,3-dihydrobenzofuran-5-yl)methyl)-3,4-dimethoxy-N-
phenylbenzenesulfonamide (16a).  To a solution of 15a (100 mg, 0.395 mmol) in DCM (5 ml) 
was added triethylamine (0.17 mL, 0.790 mmol) and 3,4 dimethoxybenzenesulfonylchloride 
(187 mg, 0.790 mmol) dissolved in 1mL of DCM and allowed to stir for 72 hours.  Ammonium 
chloride was added to the reaction mixture, then extracted with DCM (× 2), dried over MgSO4 
and concentrated in vacuo.  The crude reaction mixture was purified by column (silica gel, 3:1 
Hx/EtOAc) to give product as a white solid – 76 mg, 42 %.  1H NMR (CDCl3) d 7.33 (dd J = 2.13, 
8.44, 1H), 7.26 - 7.21 (m, 3H), 7.09 (s, 1H)  7.00 - 6.96 ( m, 3H), 6.92 (d, J = 8.5, 1H), 6.83 (d, J 
= 8.1,1H), 6.52 (d, J = 8.1, 1H), 4.62 (s, 2H), 3.95 (s, 1H), 3.75 (s, 1H), 2.92 (s, 2H), 1.42 (s, 1H). 
13C NMR (CDCl3) 158.4, 152.5, 148.7, 139.3, 129.2, 127.5, 125.6, 121.4, 110.4, 108.9, 86.9, 
56.2, 56.0, 54.6, 42.7, 28.2. MS (ESI +): M + Na = 476. 
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General Procedure for Synthesis of compound 16b – 16f 
To a solution of 1 in methanol was added amine (1 .1 eq.), zinc chloride (2 eq.) and allowed to 
stir for 2 hours before adding NaCNBH3 (2 eq.).  The reaction was allowed to stir at room tem-
perature overnight.  The solvent was removed by rotary evaporation and the residue diluted with 
EtOAc and washed with Na2CO3 (sat) and brine.  The organic layers were dried over MgSO4 
and concentrated in vacuo.  The product was used without further purification in the next step.  
The resulting secondary amine 15 (1 eq) in DCM was added Et3N (2 eq.) and the appropriate 
aryl or alkyl sulfonyl chloride (1.1 eq) and the reaction allowed to stir at room temperature over-
night.  The reaction mixture was diluted with DCM and washed with water and brine.  The or-
ganic layer was dried over Na2SO4 and concentrated in vacuo.  The crude product was purified 
by flash chromatography. 
 
N-Cycloheptyl-N-((2,2-dimethyl-2,3-dihydrobenzofuran-5-yl)methyl)-3,4-
dimethoxybenzenesulfonamide (16b).  Yield: 14%.  1H NMR ( CDCl3)  7.43 (dd, J = 2.14, 
8.44, 1H), 7.25 – 7.24 (m, 2H), 7.05 (d, J = 8.13, 1H), 6.92 (d, J = 8.5, 1H), 6.65 (d, J = 8.1, 1H), 
4.28 (s, 2H), 3.96 (s, 3H), 3.90 (s, 3H), 3.00 (s, 2H), 1.63 -1.51 (m, 8H), 1.48 (s, 6H), 1.45 -1.27 
(m, 7H). HRMS (ESI +):  C26H35 NO5S + Na: observed: 496.2122,  calculated: 496.2134,  
 
N-((2,2-Dimethyl-2,3-dihydrobenzofuran-5-yl)methyl)-N-isopropyl-
3,4dimethoxybenzenesulfonamide (16c).  Yield: 84%.  1H NMR (CDCl3)  7.45 (d, J = 8.2 Hz, 
1H), 7.27 (s, 1H), 7.10 (d, J = 15.6 Hz, 1H), 6.94 (t, J = 7.5 Hz, 2H), 6.63 (d, J = 7.6 Hz, 1H), 
4.24 (s, 2H), 3.94 (d, J = 19.3 Hz, 6H), 3.05 – 2.93 (m, 2H), 2.91 (d, J = 6.9 Hz, 2H), 1.82 – 1.66 
(m, 1H), 1.48 (s, 6H), 0.77 (d, J = 5.7 Hz, 6H).  13C NMR (CDCl3) 158.5, 152.2, 149.0, 132.1, 
128.4, 127.9, 127.7, 125.6, 121.1, 110.5, 109.9, 109.0, 87.1, 77.4, 77.1, 76.7, 56.2, 56.2, 55.8, 
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52.4, 42.7, 28.1, 26.9, 20.0.  HRMS (ESI+): C23H31NO5S + Na: observed: 456.1833, calculated: 
456.1821,  
 
N-Butyl-N-((2,2-dimethyl-2,3-dihydrobenzofuran-5-yl)methyl)-3,4-
dimethoxybenzenesulfonamide (16d).  Yield: 18%.  1H NMR (CDCl3)  7.47 (dd, J = 8.4, 1.5 
Hz, 1H), 7.34 – 7.22 (m, 2H), 7.13 (s, 1H), 6.96 (d, J = 8.4 Hz, 2H), 6.65 (d, J = 8.1 Hz, 1H), 
4.25 (s, 2H), 3.95 (d, J = 16.7 Hz, 6H), 3.22 – 3.03 (m, 2H), 2.99 (s, 2H), 1.57 (d, J = 21.8 Hz, 
1H), 1.49 (s, 6H), 1.41 – 1.24 (m, 3H), 1.23 – 1.08 (m, 2H), 0.79 (t, J = 7.3 Hz, 3H).  13C NMR 
(CDCl3)  158.6, 152.2, 149.2, 143.0, 132.3, 128.3, 127.4, 125.5, 120.9, 110.5, 109.8, 109.0, 
87.1, 77.4, 77.0, 76.7, 56.2, 56.2, 51.3, 47.3, 42.7, 29.9, 28.1, 19.9, 13.7.  HRMS (ESI +): 
C23H31NO5S + Na: observed: 456.1812, calculated: 456.1821  
N-Cyclohexyl-N-((2,2-dimethyl-2,3-dihydrobenzofuran-5-yl)methyl)-3,4-
dimethoxybenzenesulfonamide(16e).  Yield: 36%.  1H NMR (CDCl3)  7.41 (d, J = 8.4, 1H), 
7.22 (s, 2H), 7.03 ( d, J = 7.9, 1H), 6.90 (d,  J = 8.3, 1H), 6.63 (d, J = 7.9, 1H), 4.31 (s, 2H), 3.70 
( 1H) 3.94 (s, 3H) 3.88 (s, 3H), 2.98 (s, 1H), 1.69 – 1.52 (m, 7H),  1.47(s, 6H),  1.27-1.22 (m, 
4H).  HRMS (ESI +): C25H33 NO5S + Na:  observed: 482.1981, calculated:  482.1977. 
N-Cyclopentyl-N-((2,2-dimethyl-2,3-dihydrobenzofuran-5-yl)methyl)-3,4-
dimethoxybenzenesulfonamide (16f). Yield: 31% 1H NMR (CDCl3) 7.44 (d, J = 8.5, 1H), 
7.27 (s, 2H), 7.04 (d, J = 8.10, 1H), 6.92 (d, J = 8.4, 1H), 6.65 ( d, J = 8.1, 1H), 4.29 (s, 3H), 
3.95 (s, 3H), 3.90 (s, 3H), 2.99 (s, 2H), 1.85 -1.58 (m, 3H), 1.60 – 1.22 (m, 12 H).  HRMS (ESI 
+): C24H31NO5S + Na:  observed: 468.1817, calculated: 468.1821. 
2,2-Dimethyl-2H-pyrano[2,3-b]pyridine-6-carbaldehyde (18).  To a solution of 17(100 mg, 
0.390 mmol) in dry ether (2 ml) was added BuLi (0.25 mL, 2.5 M solution in THF) dropwise at -
65 ˚C and stirred for 15 minutes.  Then DMF was added dropwise and stirred at -65 ˚C for 1.5 
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hours.  Water was added to quench the reaction and extracted with EtOAc (×2).  The organic 
layers were washed with water (×1), brine (×1), dried over MgSO4 and concentrated in vacuo to 
give a yellow oil.  Purification by column chromatography 6:1 Hx/EtOAc to give white solid 23 
mg (31 %).  1H NMR (CDCl3)  1.58 (s, 1H); 5.79 (d, 1H, J = 8), 6.36 (d, 1H, J = 9.6), 7.76 (s, 
1H), 8.50 (s, 1H), 9.92 (s, 1H).  
 
 N-((2,2-Dimethyl-2H-pyrano[2,3-b]pyridin-6-yl)methyl)benzenamine (19a).  To a solution of 
2,2-dimethyl-2H-pyrano[2,3-b]pyridine-6-carbaldehyde 18 (20 mg, 0.106 mg) in methanol (1ml) 
was added aniline (0.01 ml, 0.12 mmol), NaCNBH3 (13 mg, 0.212 mmol) and ZnCl2 (29 mg, 
0.212 mmol).  The reaction was allowed to stir for 30 minutes after which the solvent was re-
moved by rotary evaporation and the 1M NaOH added to the residue, extracted with DCM, dried 
over MgSO4 and concentrated in vacuo.  Purified by column chromatography (3:1 Hx/EtOAc) to 
give a white solid 20 mg (72%).1H NMR (CDCl3):  8.01 (s, 1H), 7.29 (s, 1H), 7.26 – 7.16 (m, 
2H), 6.74 (t, J = 7.2 Hz, 1H), 6.63 (d, J =  8.0 Hz, 1H), 6.26 (d, J = 9.6 Hz, 1H), 5.67 (d, J = 9.6 
Hz, 1H), 4,21 (s, 2H), 1.51(s, 6H). 13C NMR (CDCl3): d 159.6, 147.8, 146.4, 133.8, 132.2, 129.3, 
128.4, 120.9, 118.0, 115.4, 113.0, 79.2, 45.4, 28.8. 
 
N-((2,2-Dimethyl-2H-pyrano[2,3-b]pyridin-6-yl)methyl)cyclohexanamine (19b).  To a solu-
tion of 2,2-dimethyl-2H-pyrano[2,3-b]pyridine-6-carbaldehyde 18 (23 mg, 0.121 mmol)  in MeOH 
(1mL) was added cyclohexylamine (0.014 ml, 0.121 mmol), NaCNBH3 ( 15 mg, 0.242 mmol) 
and Zinc chloride (33 mg, 0.242 mmol) and stirred overnight .  The solvent was removed by ro-
tary evaporation and the residue dissolved in EtOAc and washed with 1M NaOH, water and 
brine, dried over MgSO4 and concentrated in vacuo.  The product was used in the next step 
without further purification.  
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N-((2,2-Dimethyl-2H-pyrano[2,3-b]pyridin-6-yl)methyl)-3,4-dimethoxy-N-
phenylbenzenesulfonamide (20a).  To a solution of I9a (20 mg, 0.075 mmol) in DCM (1mL) 
was added 3,4-dimethoxybenzenesulfonyl chloride (36 mg, 0.150 mmol) and triethylamine 
(0.021 ml, 0.150 mmol).  The reaction was allowed to stir for 24 hours at room temperature.  
The reaction mixture was washed with water (× 2) and the organic layer dried over MgSO4 and 
concentrated in vacuo.  Column chromatography (2:1 hexane/EtOAc) gave a white solid. Yield 
43%. 1H NMR (CDCl3)  1.47 (s, 6H), 3.76 (s, 3H), 3.97 (s, 3H), 4.60 (s, 2H), 5.66 (d,1H, J = 
9.6), 6.26 (d, 1H, J = 10), 6.93 – 6.99 (m, 4H), 7.23 – 7.25 (m, 3H), 7.32 – 7.36 (m, 2H), 7.63 (d, 
1H, J = 2.4).  HRMS (ESI +): C25H25N2O5S + Na: observed: 467.1636, calculated: 467.1641. 
 
N-Cyclohexyl-N-((2,2-dimethyl-2H-pyrano[2,3-b]pyridin-6-yl)methyl)-3,4-
dimethoxybenzenesulfonamide (20b). Yield: 60%.  1H NMR (CDCl3):  7.89 (s, 1H), 7.49 (s, 
1H), 7.44 (d, J = 2.0 Hz, 1H), 7.28 (s, 1H), 6.93 (d, J = 8.8 Hz, 1H), 6.31 (d, J = 10 Hz, 1H), 5.69 
(d, J =10 Hz, 1H), 4.30 (s, 2H), 3.95 (s, 3H), 3.91 (s, 3H), 1.71 – 1.52 (m, 10 H), 1.29 – 1.21 (m, 
6H). HRMS (ESI +): C25H32N2O5S + H: observed: 473.2127, calculated: 473.2110. 
 
6-Bromo-2,2-dimethyl-2H-pyrano[3,2-b]pyridine(23).  To a solution 2-methyl-3-butyn-2-ol (21) 
in acetonitrile (6 mL) was added DBU (0.80 mL, 6.61 mmol) at 0oC, then TFAA was added 
dropwise, also at 0oC.  The reaction was allowed to stir for 30 minutes.  In another round bottom 
flask, DBU (0.80 ml, 6.61 mmol) was added to a solution of 2-bromo-5-hydroxy pyridine (1.0 g, 
5.75 mmol) in 6 ml of acetonitrile at 0oC. The 2-methyl-3-butyn-2-ol reaction was then added 
dropwise into this reaction and allowed to stir for 30 additional minutes.  The solvent was re-
moved by rotary evaporation and the residue diluted with DCM and the organic layer washed 
with 1M HCl, 1M NaOH, sat NaHCO3 and brine.  The organic layer was dried over MgSO4 and 
concentrated in vacuo.  The crude product was dissolved in 2 mL of xylene and subjected to 
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microwave irradiation (130 ˚C, 220 W) for 30 minutes.  The solvent was removed by rotary eva-
poration and the product concentrated in vacuo.  The crude product was purified by column 
chromatography (10:1 Hx/EtOAc) to give a 300 mg of a yellow solid (22% for two steps). 1H-
NMR: 1.45 (s, 6H), 5.86 (d, 1H, J = 10.4), 6.44 (d, 1H, J = 10), 6.90 (d, 1H, J = 8.8), 7.14 (s, 1H, 
J = 8.4).  HRMS (ESI+): C10H11NOBr: observed: 240.0026, calculated: 240.0024,  
 
2,2-Dimethyl-2H-pyrano[3,2-b]pyridine-6-carbaldehyde(24).  To a solution of 23 (200 mg, 
0.83 mmol) in anhydrous THF (5 mL) at -78 ˚C was added BuLi (2.5 M, 0.35 ml) and allowed to 
stir for 35 minutes, then DMF (0.08 mL, 0.1 mmol) was added dropwise.  The reaction was 
stirred at -78°C for 30 additional minutes.  Water (3 mL) was added to quench the reaction and 
was extracted with EtOAc.  The organic layer was washed with water, brine, dried over MgSO4 
and concentrated in vacuo.  Column chromatography 10:1 Hx/EtOAc gave the product as yello-
wish solid (23% yield).  1H NMR: 1.53 (s, 6H), 6.01 (d 1H, J = 10.4), 6.58 (d, 1H, J = 10.4 ), 7.13 
(d, 1H, J = 8.4 ), 7.77 (d, 1H, J = 8.4), 9.93 (s, 1H). 13C NMR: 28.8, 78.7, 123.0, 123.3, 123.4, 
136.3, 145.8, 153.7, 191.2.  
 
N-((2,2-Dimethyl-2H-pyrano[3,2-b]pyridin-6-yl)methyl)aniline (25a).  To a solution of 2,2-
dimethyl-2H-pyrano[3,2-b]pyridine-6-carbaldehyde (434 mg, 2.28 mmol) in methanol (3 mL) was 
added aniline (0.3 mL, 2.52 mmol) and zinc chloride (621 mg, 4.56 mmol) and stirred at room 
temperature for 2 hours.  Then NaCNBH3 (287 mg, 4.56 mmol) was added and stirred overnight. 
Purification by column: 4: 1 Hx/ EtOAc to give an off-white solid. Yield: (203 mg, 48%).  1H NMR 
(CDCl3): 1.49 (s, 6H), 4.361 (s, 2H), 5.91 (d, 1H, J = 10), 6.55 ( d, 1H, J = 10), 6.68 – 6.71 (m, 
3H), 7.01 (d, 1H, J = 8.4), 7.08 (d, 1H, J = 8.4), 7.18 – 7.38 (m, 2H).  
 
N-((2,2-Dimethyl-2H-pyrano[3,2-b]pyridin-6-yl)methyl)-3,4-dimethoxy-N-
phenylbenzenesulfonamide (26a).  To a solution of 25a (60 mg, 0.237 mmol) in diclorome-
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thane (2.5 ml) was added triethylamine (0.07 mL, 0.474 mmol) and the 3,4 dimethoxybenzene-
sulfonyl chloride (84 mg, 0.355 mmol)), the reaction was allowed to stir for 24 hours.  The reac-
tion mixture diluted with DCM and the organic layer washed with then water and brine and dried 
over magnesium sulfate and concentrated in vacuo.  The crude product was purified by column 
chromatography: silica gel; 3:1 Hexane/EtOAc to 1:1 Hexane/EtOAc to give an off-white solid 
55.8 mg (50 %).   1H NMR (CDCl3)  7.29 (dd, J = 8.4, 2.1 Hz, 2H), 7.25 – 7.17 (m, 3H), 7.14 – 
7.09 (m, 2H), 6.96 (d, J = 8.4 Hz, 1H), 6.92 – 6.86 (m, 2H), 6.32 (d, J = 10.1 Hz, 1H), 5.80 (d, J 
= 10.1 Hz, 1H), 4.78 (s, 2H), 3.94 (s, 3H), 3.72 (s, 3H), 1.40 (s, 6H).  HRMS (ESI +): 
C25H26N2O5S: observed 467.1641, calculated: 467.1641. 
 
General Procedure for synthesis of 26b – 26j by alkyl sulfonation .  To a solution of 25 (1 
eq) in methanol was added the primary amine (1 eq), ZnCl2 (2 eq) and NaCNBH3 (2 eq) and al-
lowed to stir at room temperature for 4 hours to overnight.  The solvent was removed by rotary 
evaporation, and then the residue was dissolved in EtOAc, which was washed with 1M NaOH, 
water ad brine.  The organic layer was dried over MgSO4 and concentrated in vacuo.  The crude 
secondary amine was used without further purification. 
  To a solution of the secondary amine (1 eq) in dichloromethane was added triethylamine (3 eq) 
and the sulfonylchloride (1.5 eq), the reaction was allowed to stir for 24 to 48 hours, then water 
was added and the organic layer extracted with dichloromethane, dried over magnesium sulfate 
and concentrated in vacuo and purified by flash column chromatography.   
 
N-Butyl-N-((2,2-dimethyl-2H-pyrano[3,2-b]pyridin-6-yl)methyl)-3,4-
dimethoxybenzenesulfonamide (26b).  Yield: 42%.  1H NMR (CDCl3)  7.47 (d,  J = 2.4 Hz, 
1H), 7.29 – 7.26 (m, 2H), 7.04( d, J = 8.4, 1H), 6.94 (d, J = 8.8, 1H), 6.40 (d, J = 8.0, 1H), 5.88 
( d, J = 10, 1H), 4.37 (s, 1H), 3.96 (s, 3H), 3.93 (s, 3H),  3.18 (t, J = 7.6, 2H), 1.48 (s, 1H), 1.38 
66 
 
(m, 2H), 1.18 (sx, J = 7.2, 2H), 0.79 (t, J = 7.2, 3H).  13C NMR (CDCl3) δ 152.4, 149.0, 148.8, 
148.7, 135.4, 131.6, 123.7, 123.7, 122.7, 121.0, 110.5, 109.8, 56.2, 56.2, 53.3, 48.8, 30.2, 28.2, 
19.9, 13.6.  HRMS (ESI +): C23H31N2O5S: observed: 447.1937, calculated: 447.1954 
 
N-(3,4-Dimethoxyphenyl)-N-((2,2-dimethyl-2H-pyrano[3,2-b]pyridin-6-yl)methyl)-3,4-
dimethoxybenzenesulfonamide (26c).  Yield: 51%. 1H NMR (CDCl3) 7.32 – 7.38 (m, 
2H),7.01 – 6.98 (m, 2H), 6.91 (d, J = 8.4 Hz, 1H), 6.66 (d, J= 8.4 Hz. 1H), 6.68 – 6.62 (m, 2H), 
6.34 (dd, J = 12.0, 0.4 Hz), 5.82 (d, J = 10.0 Hz, 1H), 4.76 (s, 2H), 3.96 (s, 3H), 3.83 (s, 3H), 
3.79 (s, 3H), 3.72 (s, 3H), 1.43 (s, 6H).   13C NMR (CDCl3 ) δ 152.6, 148.7, 148.7, 148.6, 148.5, 
147.8, 140.2, 135.3, 132.2, 129.6, 123.6, 123.6, 122.6, 121.8, 121.0, 112.5, 110.5, 110.3, 56.2, 
56.1, 56.1, 55.9, 28.2.  HRMS (ESI +): C27H31N2O7S: observed: 527.1866, calculated: 527.1852. 
  
N-Cyclopentyl-N-((2,2-dimethyl-2H-pyrano[3,2-b]pyridin-6-yl)methyl)-3,4-
dimethoxybenzenesulfonamide (26d).  Yield: 31%.  1H NMR (CDCl3) δ 7.55 – 7.35 (m, 2H), 
7.35 – 7.22 (m, 1H), 7.07 (d, J = 8.4 Hz, 1H), 6.98 – 6.86 (m, 1H), 6.46 (dd, J = 14.7, 10.2 Hz, 
1H), 5.89 (d, J = 10.1 Hz, 1H), 4.44 – 4.24 (m, 3H), 3.96 (s, 3H), 3.93 (s, 3H), 1.76 – 1.15 (m, 
15H).  13C NMR (CDCl3)  152.4, 150.7, 148.5, 135.4, 132.2, 123.8, 123.7, 121.9, 121.2, 110.5, 
109.8, 59.4, 56.3, 56.2, 48.6, 29.1, 28.2, 23.4.  HRMS (ESI+): C24H31N2O5 : observed: 459.1938, 
calculated: 459.1954. 
 
N-Cyclohexyl-N-((2,2-dimethyl-2H-pyrano[3,2-b]pyridin-6-yl)methyl)-3,4-
dimethoxybenzenesulfonamide (26e).  Yield: 46%. 1H NMR  (CDCl3) 7.47 (dd, J = 2.4, 6.4 Hz, 
1H), 7.42 (d, J = 8.4 Hz, 1H), 7.30 (d, J = 2.4 Hz, 1H), 7.06 (d, J = 8.4, 1H), 6.93 (d, J = 8.8 Hz, 
1H), 6.45 (d, J = 10 Hz, 1H), 5.88 (d, J = 10 Hz, 1H), 3.96 (s, 3H), 3.92 (s, 3H), 3.80 (m, 1H), 
1.64 (m, 3H), 1.48 (m, 9H), 1.25 -1.20 (m, 4H).  13C NMR (CDCl3) δ 152.2, 150.7, 149.1, 148.5, 
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139.9, 135.2, 133.2, 123.7, 123.7, 122.5, 120.7, 110.6, 109.5, 58.4, 56.2, 56.1, 48.5, 31.3, 28.2, 
26.1, 25.2.  HRMS (ESI +):  C25H33 N2O5S: observed: 473.2118, calculated: 473.2110. 
N-((2,2-Dimethyl-2H-pyrano[3,2-b]pyridin-6-yl)methyl)-3,4-dimethoxy-N-(5,6,7,8-
tetrahydronaphthalen-2-yl)benzenesulfonamide (26f).  1H NMR (CDCl3) δ 7.39 – 7.31 (m, 
2H), 6.99 (dd, J = 13.4, 5.2 Hz, 2H), 6.92 (dd, J = 8.1, 2.8 Hz, 2H), 6.81 (d, J = 7.6 Hz, 2H), 6.35 
(d, J = 10.1 Hz, 1H), 5.94 – 5.71 (m, 1H), 4.78 (d, J = 25.5 Hz, 2H), 3.97 (s, 3H), 3.79 (d, J = 5.3 
Hz, 3H), 2.65 (dd, J = 25.6, 13.3 Hz, 4H), 1.83 – 1.66 (m, 4H), 1.41 (d, J = 16.1 Hz, 6H). MS 
(ESI +): M + H = 521 
 
N-Cycloheptyl-N-((2,2-dimethyl-2H-pyrano[3,2-b]pyridin-6-yl)methyl)-3,4-
dimethoxybenzenesulfonamide (26g).  Yield: 18%. 1H NMR (CDCl3) δ 7.47 (dt, J = 4.4, 2.2 
Hz, 1H), 7.44 (d, J = 8.4 Hz, 1H), 7.31 – 7.27 (m, 1H), 7.07 (d, J = 8.4 Hz, 1H), 6.94 (dd, J = 8.5, 
4.9 Hz, 1H), 6.45 (dd, J = 10.1, 0.5 Hz, 1H), 5.88 (d, J = 10.1 Hz, 1H), 4.44 – 4.29 (m, 2H), 3.96 
(s, 3H), 3.94 (s, 1H), 3.93 (s, 3H), 1.62 – 1.29 (m, 18H).  
 
N-Cyclooctyl-N-((2,2-dimethyl-2H-pyrano[3,2-b]pyridin-6-yl)methyl)-3,4-
dimethoxybenzenesulfonamide (26h).  Yield: 45%. 1H NMR (CDCl3)  7.49 (d, J = 6.4, 1H), 
7.46 (d, J = 10, 1H), 7.32 – 7.29 (m, 1H), 7.07 (d, J = 8.0, 1H), 6.94 (d, J = 8.4, 1H), 6.45 (d, J = 
10, 1H), 5.89 (d, J = 10, 1H), 4.38 (s, 2H),  3.97 – 3.93 (m, 7H ), 1.61 – 1.42 ( m, 20H ). MS 
(ESI+): M + H: 501.2  
 
N-Cyclobutyl-N-((2,2-dimethyl-2H-pyrano[3,2-b]pyridin-6-yl)methyl)-3,4-
dimethoxybenzenesulfonamide (26i).  Yield: 40%. 1H NMR (CDCl3) δ 7.44 (dd, J = 8.4, 2.2 
Hz, 1H), 7.36 (d, J = 8.4 Hz, 1H), 7.31 – 7.21 (m, 2H), 7.07 (d, J = 8.4 Hz, 1H), 6.94 (t, J = 6.9 
Hz, 1H), 6.40 (dd, J = 32.8, 10.0 Hz, 1H), 5.88 (t, J = 10.6 Hz, 1H), 4.49 – 4.28 (m, 3H), 3.96 (s, 
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3H), 3.93 (d, J = 3.0 Hz, 3H), 2.08 – 1.83 (m, 4H), 1.60 – 1.40 (m, 8H).  13C NMR (CDCl3) δ 
152.5, 150.3, 149.0, 148.6, 140.1, 135.4, 131.7, 123.8, 123.7, 121.8, 121.0, 110.5, 109.6, 77.3, 
77.0, 76.7, 56.2, 56.2, 52.7, 49.3, 28.9, 28.2, 15.0. M + H = 445. 
 
N-((2,2-Dimethyl-2H-pyrano[3,2-b]pyridin-6-yl)methyl)-N-(4-fluorophenyl)-3,4-
dimethoxybenzenesulfonamide (26j).   Yield: 12%.  1H NMR (CDCl3) δ 7.55 – 7.40 (m, 1H), 
7.38 – 7.23 (m, 3H), 7.16 – 7.01 (m, 4H), 7.00 – 6.87 (m, 5H), 6.40 (t, J = 11.7 Hz, 1H), 5.88 (t, 
J = 13.4 Hz, 1H), 4.83 (d, J = 14.0 Hz, 2H), 3.97 (s, 3H), 3.86 – 3.73 (m, 3H), 1.44 (s, 6H).  
HRMS (ESI +) C25H25FN2O5S + H: observed: 485.1531, calculated: 485.1546. 
General Procedure for 26k – 26t.  To a solution of 25a (1 eq) in pyridine at 0˚C, was added the 
appropriate sulfonyl chloride dropwise. The reaction was allowed to warm up to room tempera-
ture overnight. The reaction mixture was then diluted with EtOAc and the organic layer washed 
with 10% citiric acid and sat. NaHCO3, water and brine.  Ther organic layer was dried over 
MgSO4, concentrated in vácuo, and purified by column chromatography (silica gel). 
N-((2,2-Dimethyl-2H-pyrano[3,2-b]pyridin-6-yl)methyl)-N-phenylcyclohexanesulfonamide 
(26k).  Yield: 60%.  1H NMR (CDCl3):  7.30 – 7.22 (m, 4H), 7.07 – 7.01 (m, 2H), 6.90 (dd, J = 
24.2, 1.8 Hz, 1H), 6.46 (dd, J = 29.3, 2.1 Hz, 1H), 5.86 (d, J = 29.3 Hz, 1H), 5.05 (d, J = 48.2 
Hz, 1H), 4.90 (d, J = 48.2 Hz, 1H), 2.13 – 1.96 (m, 4H), 1.78- 1.70 (m, 5H), 1.44 (d, J = 6.3 Hz, 
6H), 1.27 (m, 2H).  13C NMR (CDCl3): δ 148.5, 148.3, 143.6, 140.4, 135.2, 129.1, 123.9, 123.8, 
123.6, 122.0, 121.8, 92.4, 34.5, 31.8, 28.3, 28.2, 24.7, 21.7, 21.3. 
 
N-((2,2-Dimethyl-2H-pyrano[3,2-b]pyridin-6-yl)methyl)-N-phenylpropane-2-sulfonamide 
(26l).  Yield: 58%.  1H NMR (CDCl3): δ 7.37 – 7.19 (m, 4H), 7.16 – 6.99 (m, 2H), 6.93 (t, J = 9.4 
Hz, 1H), 6.46 (dd, J = 10.1, 0.5 Hz, 1H), 5.87 (d, J = 10.1 Hz, 1H), 4.92 (dd, J = 36.5, 16.5 Hz, 
2H), 1.81 (s, 3H), 1.75 (d, J = 11.8 Hz, 4H), 1.45 (t, J = 5.8 Hz, 6H).  13C NMR (CDCl3):  148.5, 
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148.2, 143.1, 140.5, 135.3, 129.1, 124.2, 123.7, 123.6, 122.2, 122.1, 86.0, 28.3, 28.2, 27.4, 
25.4.  
 
N-((2,2-Dimethyl-2H-pyrano[3,2-b]pyridin-6-yl)methyl)-N-phenylcyclopropanesulfonamide 
(26m).  Yield: 46%.  1H NMR (CDCl3) δ 7.44 – 7.42 (m, 2H), 7.34 – 7.23 (m, 4H), 6.99 (d, J = 8 
Hz, 1H), 6.40 (d, J = 10, 1H), 5.85 (dd, J = 10, 1H), 4.98 (s, 2H), 2.55 (m, 1H), 1.44 (d, J = 16.1 
Hz, 6H), 1.13- 1.11 (m, 2H), 0.98-0.95 (m, 2H).  13C NMR (CDCl3)  148.7, 148.1, 140.4, 139.7, 
135.3, 129.1, 128.8, 127.7, 123.7, 123.6, 122.4, 56.2, 28.6, 28.2, 5.16. HRMS (ESI+) for 
C20H22N2O3S + Na: observed: 393.1231, calculated: 393.1249. 
 
N-((2,2-Dimethyl-2H-pyrano[3,2-b]pyridin-6-yl)methyl)-N-phenylbutane-1-sulfonamide 
(26n).  Yield: 48%.  1H NMR (CDCl3) δ 7.41 – 7.29 (m, 4H), 7.27 – 7.22 (m, 1H), 7.18 (d, J = 8.3 
Hz, 1H), 7.00 (dd, J = 12.4, 5.5 Hz, 1H), 6.41 (d, J = 10.1 Hz, 1H), 5.86 (d, J = 10.1 Hz, 1H), 
4.94 (s, 2H), 3.38 – 2.79 (m, 2H), 1.96 – 1.77 (m, 2H), 1.54 – 1.38 (m, 8H), 1.12 – 0.77 (m, 3H).  
13C NMR (CDCl3) 170.9, 148.8, 148.2, 139.6, 135.4, 129.3, 128.3, 127.6, 123.7, 123.2, 122.5, 
56.3, 51.3, 28.2, 25.3, 21.7, 13.6. MS (ESI +): M + H = 387.2 
 
N-((2,2-Dimethyl-2H-pyrano[3,2-b]pyridin-6-yl)methyl)-N-phenylpropane-1-sulfonamide 
(26o).  Yield: 20%.  1H NMR (CDCl3) δ 7.40 – 7.21 (m, 6H), 7.17 (d, J = 8.3 Hz, 1H), 6.98 (t, J = 
7.2 Hz, 1H), 6.40 (d, J = 10.1 Hz, 1H), 5.85 (d, J = 10.1 Hz, 1H), 4.93 (s, 2H), 3.20 – 2.99 (m, 
2H), 1.98 – 1.79 (m, 2H), 1.43 (s, 6H), 1.03 (t, J = 7.4 Hz, 3H).  13C NMR (CDCl3) δ 148.8, 
148.2, 139.6, 135.4, 129.3, 128.4, 127.6, 123.7, 123.6, 122.5, 77.3, 77.0, 76.7, 56.2, 53.2, 28.2, 
17.1, 13.1. MS (ESI+): M +H = 373.0 
 
N-((2,2-Dimethyl-2H-pyrano[3,2-b]pyridin-6-yl)methyl)-2-methyl-N-phenylpropane-1-
sulfonamide (26p).  Yield: 28%. 1H NMR (CDCl3) δ 7.40 – 7.30 (m, 4H), 7.27 – 7.21 (m, 1H), 
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7.19 (d, J = 8.3 Hz, 1H), 6.99 (d, J = 8.3 Hz, 1H), 6.42 (d, J = 10.1 Hz, 1H), 5.89 (dd, J = 21.3, 
10.0 Hz, 1H), 4.93 (s, 2H), 3.01 (dd, J = 14.1, 6.5 Hz, 2H), 2.34 (dp, J = 13.3, 6.7 Hz, 1H), 1.47 
(d, J = 14.5 Hz, 6H), 1.10 (d, J = 6.7 Hz, 6H).  MS (ESI+): M + H = 387 
 
N-((2,2-Dimethyl-2H-pyrano[3,2-b]pyridin-6-yl)methyl)-N-phenylbiphenyl-4-sulfonamide 
(26q).  Yield: 17%.   1H NMR (CDCl3) δ 7.69 (s, 4H), 7.67 – 7.60 (m, 2H), 7.57 – 7.41 (m, 3H), 
7.36 – 7.22 (m, 5H), 7.21 – 7.13 (m, 2H), 7.00 (t, J = 7.3 Hz, 1H), 6.34 (d, J = 10.1 Hz, 1H), 5.83 
(t, J = 9.5 Hz, 1H), 4.86 (d, J = 5.9 Hz, 2H), 1.43 (s, 6H).  HRMS (ESI +): C29H27N2O3S:  ob-
served: 483.1723, calcul;ated: 483.1742,  
 
N-((2,2-Dimethyl-2H-pyrano[3,2-b]pyridin-6-yl)methyl)-N-phenylbenzo[d][1,3]dioxole-4-
sulfonamide (26r).  Yield: 65%.  1H NMR (CDCl3) δ 7.35 – 7.21 (m, 4H), 7.21 – 7.12 (m, 3H), 
7.08 (t, J = 3.9 Hz, 1H), 7.02 – 6.93 (m, 1H), 6.88 – 6.78 (m, 1H), 6.36 (dd, J = 10.1, 0.5 Hz, 
1H), 6.09 (s, 2H), 5.84 (dd, J = 14.0, 9.0 Hz, 1H), 4.82 (s, 2H), 1.68 (s, 2H), 1.43 (s, 6H).  HRMS 
(ESI+): C24H23N2O5S: observed: 451.1316. calculated: 451.1328,  
 
N-((2,2-Dimethyl-2H-pyrano[3,2-b]pyridin-6-yl)methyl)-N-phenylquinoline-8-sulfonamide 
(26s) .  Yield: 65%.  1H NMR (CDCl3) δ 9.19 (dd, J = 4.2, 1.8 Hz, 1H), 8.43 – 8.16 (m, 2H), 8.00 
(dt, J = 10.5, 5.3 Hz, 1H), 7.66 – 7.56 (m, 2H), 7.54 – 7.47 (m, 1H), 7.14 – 6.94 (m, 6H), 6.40 (d, 
J = 10.1 Hz, 1H), 5.85 (t, J = 15.1 Hz, 1H), 5.58 (d, J = 35.1 Hz, 2H), 1.45 (s, 6H).  13C NMR 
(CDCl3) δ 151.3, 150.0, 148.5, 144.2, 140.1, 139.6, 137.1, 136.5, 135.1, 133.7, 133.5, 128.8, 
128.8, 128.2, 127.2, 125.4, 123.9, 123.8, 122.4, 122.1, 77.4, 77.1, 76.9, 76.7, 58.8, 28.2.  
HRMS (ESI+): C26 H24 N3O3S: observed: 485.1543, calculated: 485.1538. 
 
N-((2,2-Dimethyl-2H-pyrano[3,2-b]pyridin-6-yl)methyl)-N-phenyl-2,3-
dihydrobenzo[b][1,4]dioxine-6-sulfonamide (26t).  Yield: 57%.  1H NMR (CDCl3):  1.419 (s, 
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6H), 4.33-4.28 (m, 2H), 4.81 (s, 2H), 5.82 (d, 1H, J=10), 6.35 (d, 1H, J = 10), 6.89 (d,1H, J = 
8.4), 6.97 ( d, 1H, J = 8.4), 7.06 (dd, 1H), 7.12 -7.15 (m, 2H), 7.20 – 7.3 (m, 5H).  13C NMR (101 
MHz, CDCl3) δ 148.6, 147.7, 147.5, 143.4, 140.4, 139.4, 135.2, 130.4, 128.8, 128.5, 127.6, 
123.7, 123.6, 122.4, 121.6, 117.4, 117.4, 77.4, 77.1, 77.0, 76.7, 64.6, 64.1, 60.4, 55.7, 28.2, 
21.1, 14.2.  HRMS (ESI+): C15H15N2O5S: observed: 465.1489, calculated: 465.1484. 
 
N-((2,2-Dimethyl-2H-pyrano[3,2-b]pyridin-6-yl)methyl)-3,4-dimethoxy-N-phenylbenzamide 
(27).  To a solution of N-((2,2-dimethyl-2H-pyrano[3,2-b]pyridin-6-yl)methyl)aniline 25a ( 60 mg, 
0.226 mmol) in DCM (3 mL) was added triethylamine(0.06 ml, 0.452 mmol) and 3,4-
dimethoxybenzoyl chloride (54 mg, 0.271 mmol).  The reaction was stirred overnight at room 
temperature.  The reaction mixture was washed with dH2O (×2) and sat. NaHCO3 (× 2) dried 
over MgSO4 and concentrated in vacuo.  Purification by column: silica gel: 3:1 DCM/EtOAc to 
give a light yellow oil (98 mg, 100%).  1H NMR (CDCl3) δ 7.26 – 7.17 (m, 3H), 7.17 – 7.08 (m, 
3H), 7.06 – 6.97 (m, 2H), 6.95 (t, J = 5.0 Hz, 1H), 6.66 (d, J = 8.4 Hz, 1H), 6.53 – 6.40 (m, 1H), 
5.92 – 5.79 (m, 1H), 5.16 (s, 2H), 3.83 (s, 3H), 3.66 (s, 3H), 1.46 (s, 6H).  13C NMR (CDCl3) δ 
169.9, 150.3, 149.0, 148.6, 147.9, 144.7, 140.6, 135.1, 129.0, 127.8, 127.2, 126.3, 124.0, 123.6, 
123.0, 122.3, 112.6, 109.9, 77.4, 77.0, 77.0, 76.7, 55.8, 55.7, 55.6, 28.2.  HRMS: C26H27N2O4:  
observed: 431.1951, calculated: 431.1971;  
 
2-Bromo-6-(hydroxymethyl)pyridin-3-ol (30).  A solution of 2-bromo-3-hydroxy-6-
methylpyridine 1-oxide 29 (15g, 0.075 mol) in TFAA (50 ml, 0.375 mol) was stirred at 40 °C and 
stirred for 24 hours.  The solvent was removed under vacuum.    The residue was purified by 
column chromatography, silica gel: EA:Hex (2:1) . Yield: 4.5g, 30%.  7.32 (d, J = 8.0 Hz, 1H), 
7.25 (d, J = 8.5 Hz, 1H), 4.56 (s, 2H).  
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(6-Bromo-5-(2-methylbut-3-yn-2-yloxy)pyridin-2-yl)methanol (31).  Compound 30 was dis-
solved in acetone (20 ml) and K2CO3 (166 mg, 7 mmol), KI (33 mg, 0.2 mmol), CuCl2.2H2O (33 
mg, 0.2 mmol).  The suspension was stirred at 60 oC for 10 minutes.  The solution of 3-chloro-3-
methyl2-butyne (1.02 g, 5 mmol) in acetone (5 ml) was added dropwise to the solution of 30.  
The reaction mixture was cooled to room temperature and the suspension filtered.  The solid 
residue was washed with MeOH.  The filtrate was concentrated under vacuum and purified with 
column chromatography: silica gel (EA: Hexane, 1:1).  Yield: 700 mg, 57%. 1H NMR (CDCl3):  
7.88 (d, J = 8.0 Hz, 1H), 7.23 (d, J = 8.0 Hz, 1H), 4.72 (s, 2H), 1.73 (s, 6H). 13C NMR:  154.7, 
149.6, 137.0, 129.5, 120.4, 85.7, 75.8, 75.7, 64.6, 30.1. 
(8-Bromo-2,2-dimethyl-2H-pyrano[2,3-c]pyridin-6-yl)methanol (32).  A solution of 31 (700 
mg, 2.5 mmol) in toluene (10ml) was subjected to microwave irradiation (200 W, 120 °C) for 1 
hour.  The reaction mixture was cooled to room temperature and filtered.  The filtrate was con-
centrated under vacuum ad the residue purified by column chromatography: silica gel (EA:Hex 
1:3 – 1:2).  Yield: 500 mg, 70%. 1HNMR (CDCl3):   6.88 (s, 1H), 6.28 (d, J = 10 Hz, 1H), 5.90 (d, 
J= 9.6 Hz, 1H), 4.63 (s, 2H), 1.51 (s, 6H).  
8-Bromo-6-(bromomethyl)-2,2-dimethyl-2H-pyrano[2,3-c]pyridine (33). To a solution of 32 in 
DCM (2 ml) was added CBr4 (66 mg, 0.2 mmol) and PPh3 (264 mg, 0.2 mmol).  The reaction 
mixture was stirred at room temperature for 1 hour.  The solvent was removed under vacuum 
and the residue purified by column chromatography: silica gel (EA:Hex, 1:4). Yield 260 mg, 40%. 
1H NMR (CDCl3):  6.28 (d, J = 10 Hz, 1H), 5.91 (d, J = 10 Hz, 1H), 4.47 (s, 2H), 1.53 (s, 6H).  
General Procedure for synthesis of 34. To a degassed flask with 33(1 eq) was added DMF, 
aniline (1.5 eq) and DIEA (1.5 eq).  The mixture was stirred at room temperature overnight.   
Water (50 ml) was added to the reaction mixture and the resulting solution was extracted with 
ethyl acetate (3 × 25ml).  The combined organic layer was washed with 0.5N HCl (50 ml), 40 % 
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NaHCO3 (50 ml) , water (50 ml) and brine, dried over Na2SO4 ad concentrated under vacuum.  
The residue was purified by column chromatography.   
N-((8-Bromo-2,2-dimethyl-2H-pyrano[2,3-c]pyridin-6-yl)methyl)benzenamine 34a. Yield:  
78%. 1H NMR (CDCl3)  7.26 - 7.21 (m, 3H), 6.97 -6.95 (m, 3H), 6.23 (d, J = 9.6 Hz, 1H), 5.85 
(d, J = 9.6 Hz, 1H), 4.40 (s, 2H), 1.48 (s, 6 H).  
N-((8-Bromo-2,2-dimethyl-2H-pyrano[2,3-c]pyridin-6-yl)methyl)cyclohexanamine (34b).  
Yield: 60%.  13C NMR (CD3OD)  152.0, 145.2, 136.9, 129.7, 129.1, 119.8, 118.7, 78.5, 56.0, 
49.8, 32.4, 26.8, 25.8, 24.7.  
General Procedure for synthesis of compound 35.  A flask of secondary amine 34 (1 eq) 
was degassed and THF (anh) was added under nitrogen.  The solution was cooled to -78˚C and 
stirred for 1 hour. BuLi (2.5 eq) was the added to the solution dropwise at -78 ˚C.  The resulting 
solution was stirred for 1 hour.  Water (10ml) was added to the solution and diluted with ethyl 
acetate (25ml).  After separation, the aqueous layer was extracted with Ethyl acetate and 
washed with water (25 mL × 3), brine (25 ml), dried over Na2SO4 ad concentrated under va-
cuum.  The residue was purified by column chromatography (EA: Hex, 1:4)  
N-((2,2-Dimethyl-2H-pyrano[2,3-c]pyridin-6-yl)methyl)benzenamine (35a). Yield: 70%.  1H 
NMR (CD3OD)  7.91 (s, 1H), 7.08 -7.04 (m, 3H), 6.59 – 6.57 (m, 3H), 6.28 (d, J = 9.6 Hz, 1H), 
5.92 (s, J = 10 Hz, 1H), 4.88 (s, 2H), 1.41 (s, 6H). 13C NMR (D2O)  152.3, 148.3, 148.2, 136.7, 
135.2, 128.9, 128.7, 119.9, 117.8, 116.8, 112.6, 76.9, 26.8.  
N-((2,2-Dimethyl-2H-pyrano[2,3-c]pyridin-6-yl)methyl)cyclohexanamine (35b). Yield: 50%.  
1H NMR (CD3OD)  7.95 (s, 1H), 7.08 (s, 1H), 6.44 (d, J = 9.6 Hz, 1H), 6.03 (d, J = 10 Hz, 1H), 
3.78 (s, 2H), 2.46 (m, 1H), 1.97 – 1.75 (m, 5 H), 1.46 (s, 6H, 1.27 -1.16 (m, 5H). 13C NMR 
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(CD3OD)  151.5, 148.3, 136.7, 136.5, 128.7, 119.9, 119.0, 77.0, 56.0, 50.3, 32.4, 26.8, 25.8, 
24.7.  
General procedure for Synthesis of 36.  A mixture of compound 35 (1 eq.) and the appropri-
ate sulfonyl chloride (2 eq.) in pyridine was stirred overnight at room temperature.  1 M HCl was 
added to the reaction mixture and the solution extracted with Ethyl Acetate (3 ×15 ml).  The 
combined organic layer was washed with water (3 × 20 ml), brine and dried over Na2SO4.  The 
solvent was removed under vacuum and the residue purified by column chromatography: silica 
gel (EA: Hex; 1:4). 
N-((2,2-Dimethyl-2H-pyrano[2,3-c]pyridin-6-yl)methyl)-4-methoxy-N-
phenylbenzenesulfonamide (36a). Yield: 50%. 1H NMR (CD3OD) d 7.76 (s, 1H), 7.59 – 7.56 
(m, 2H), 7.25 – 7.18 (m, 3H), 7.09 – 7.04 (m, 4H), 6.37 (d, 1H, 10 Hz) 5.97 (d, 1H, 10 Hz), 4.88 
9s, 3H), 4.78 (s, 2H), 3.084 (s, 3H), 1.40 (s, 6H). 13C NMR (CD3OD), 163.5, 148.6, 139.3, 136.7, 
136.1, 129.7, 129.3, 128.8, 128.5, 128.5, 127.6, 119.7, 119.4, 113.9, 77.1, 55.0, 54.9, 26.8. MS 
(ESI+): M + H = 437 
N-((2,2-Dimethyl-2H-pyrano[2,3-c]pyridin-6-yl)methyl)-4-nitro-N-
phenylbenzenesulfonamide (36b).   Yield: 59%. 1H NMR (CD3OD)  8.41 (dd, J = 2.0 Hz, 4.8 
Hz, 2H), 7.89 (dd, J = 2.0 Hz, 4.8 Hz), 7.78 (s, 1H), 7.29 – 7.28 (m, 4H), 7.10 – 7.08 (m, 2H), 
6.39 (d, J = 10 Hz, 1H), 6.00 (d, J = 10 Hz, 1H), 1.42 (s, 6H). MS(ESI+): M + H = 452.1 
N-Cyclohexyl-N-((2,2-dimethyl-2H-pyrano[2,3-c]pyridin-6-yl)methyl)-4-
isopropylbenzenesulfonamide (36c). Yield: 28%.  1H NMR (CDCl3)  7.98  (s, 1H), 7.77 – 
7.75 (m, 2H), 7.37 – 7.34 (m, 1H),  7.28 (d, J =- 8.8 Hz, 1H), 6.34 (d, J = 9.6 Hz, 1H), 5.84 (d, J 
= 10 Hz, 1h), 4.42 (s, 2H), 3.80 (m,. 1H), 2.99 (m, 1H), 1.75 – 1.59 (m, 3H), 1.55 – 1.39 (m, 9 H), 
1.29 – 1.27 (m, 6H), 1.23 -1.19 (m, 4H).  13C NMR (CDCl3)  153.8, 151.8, 148.1, 138.7, 136.7, 
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135.8, 128.1, 127.1, 127.0, 120.9, 118.9, 58.5, 48.7, 34.1, 28.1, 26.1, 25.1, 23.7. MS (ESI+): M 
+ H = 455. 
N-Cyclohexyl-N-((2,2-dimethyl-2H-pyrano[2,3-c]pyridin-6-yl)methyl)-3,4-
dimethoxybenzenesulfonamide (36d). Yield: 28%. 1H NMR (CDCl3)  8.00 (s, 1H), 7.50 – 
7.47 (m, 1H), 7.33 – 7.29 (m, 2H), 6.94 (d, J = 8.4 Hz, 1H), 6.36 (d, J = 9.6 Hz, 1H), 5.86 (d, J = 
9.6 Hz, 1H), 5.32 (s, 2H), 3.967 (s, 3H), 3.94 (s, 3H), 3.97 (m, 1H), 1.68 -1.52 (m, 4H), 1,48 (s, 
6H), 1.28 -1.20 (m, 4H). 13C NMR (CDCl3):  151.7, 149.1, 136.7, 135.9, 133.2, 128.1, 120.8, 
120.7, 118.9, 110.6, 109.5, 83.1, 58.5, 56.2, 56.2, 48.6, 31.4, 28.0, 26.1, 25.1. MS (ESI+): M + 
H = 473.3 
N-((2,2-dimethyl-2H-pyrano[3,2-b]pyridin-6-yl)methyl)-3,4-dimethoxy-N-phenylbenzamide 
(37).  To a solution of 25a (60 mg, 0.226 mmol) in DCM (3 ml) was added Et3N (0.06 ml, 0.452 
mmol) and 3,4dimethoxybenzenesulfonyl chloride (54 mg, 1.2 mmol) and allowed to sitr at room 
temperature overnight.  The reaction mixture was washed with d. H2O (× 2) and brine, dried 
over MgSO4 and concentrated in vacuo.  The crude product was purified by column 
chromatography silica gel: DCM/EtOAC (3:1). To give a yellow oil (98mg, 98 %).  1H NMR 
(CDCl3) δ 7.26 – 7.17 (m, 3H), 7.17 – 7.08 (m, 3H), 7.06 – 6.97 (m, 2H), 6.95 (t, J = 5.0 Hz, 1H), 
6.66 (d, J = 8.4 Hz, 1H), 6.53 – 6.40 (m, 1H), 5.92 – 5.79 (m, 1H), 5.16 (s, 2H), 3.83 (s, 3H), 
3.66 (s, 3H), 1.46 (s, 6H).  13C NMR (CDCl3) δ 169.91, 150.31, 149.00, 148.56, 147.88, 144.66, 
140.55, 135.09, 129.03, 127.77, 127.24, 126.32, 123.99, 123.55, 123.02, 122.28, 112.56, 
109.86, 77.36, 77.04, 76.98, 76.73, 55.78, 55.70, 55.62, 28.22.  HRMS (ESI+):  C26H27N2O4: ob-
served: 431.1951, calculated: 431.1971.  
 
N-((2,2-Dimethyl-2H-chromen-6-yl)methyl)-4-hydroxy-3-methoxy-N-
phenylbenzenesulfonamide (38).  To a flask containing potassium carbonate was added NMP 
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and then placed in an oil bath at 150 °C.   Benzenethiol was added and the mixture allowed to 
stir for 10 minutes, after which a solution of KCN-1 in NMP was added and the reaction allowed 
to stir at 150oC for exactly 5 minutes.  The flask was removed from the heat and immediately 
poured into ice water, then extracted with EtOAC (× 3) and the combined organic layer washed 
with water (× 3), dried over MgSO4 and concentrated in vacuo.  The crude product was purified 
by column chromatography: silica gel 50:1 (DCM: EtOAC) to give an off-white solid.  Yield: 53%. 
1H NMR:  7.32 – 7.23 (m, 1H), 7.03 – 7.00 (m, 3H), 6.99 – 6.89 (m, 2H), 6.90 (d, J = 8.4 Hz, 
1H), 6.61 (d, J = 7.6 Hz, 1H), 5.58 (d, J = 10 Hz, 1H), 4.62 (s, 2H), 3.81 (s, 3H), 1.40 (s, 6H).  
N-((2,2-Dimethyl-2H-chromen-6-yl)methyl)-4-(4-(1,3-dioxoisoindolin-2-yl)butoxy)-3-
methoxy-N-phenylbenzenesulfonamide (39).  To a solution of 38 (50.2 mg, 0.11 mmol) in 
DMF (2 mL) was added 4-bromopthalimide (34 mg, 0.12 mmol).  The reaction mixture was 
stirred at 50 °C for 3 hours.  Water was added to the reaction mixture and extracted with EtOAc 
(3 × 10 ml).  The combined organic layers was washed with brine (10 ml), dried over Na2SO4 
and concentrated under vacuum.  The crude mixture was purified by column chromatography: 
silica gel, DCM: EtOAC, 50:1. Yield: 55 mg (76%). Cdcl3 7.87 – 7.85 (m, 2H), 7.75 – 7.73 (m, 
2H), 7.31 – 7.21 (m, 5H), 7.01 – 6.89 (m, 6H), 6.60 (d, J = 7.6 Hz, 1H), 6.24 (d, J = 9.6 Hz, 1H), 
5.57 (d, J = 10Hz, 1H), 4.60 (s, 2H), 4.13 (s, 2H), 3.83 – 3.81 (m, 2H), 3.75 (m, 2H), 3.72 (s, 
3H0, 1.95 (m, 4H), 1.40 (s, 6H).  
4-(4-Aminobutoxy)-N-((2,2-dimethyl-2H-chromen-6-yl)methyl)-3-methoxy-N-
phenylbenzenesulfonamide (40).  To a solution of 39 (55.1 mg, 0.085 mmol) in 4 ml of 
EtOH:DCM (3:1) was added 51% hydrazine.  The reaction was refluxed for 2 hours, and then 
allowed to stir at r.t. overnight.  The solvent was removed, and DCM was added to the residue.  
The white insoluble material was filtered and the filtrate was collected.  The solvent was re-
moved under vacuum.  The crude product was purified by column chromatography: silica gel, 
DCM: MeOH: Et3N (100:5:1) to give an off white solid. Yield: 30.2 mg (67%). 1H NMR  7.33 – 
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7.22 (m, 4H), 7.02 -6.98 (m, 3H), 6.92 – 6.89 (m, 3H), 6.60 (d, J = 8.0 Hz, 1H), 6.24 (d, J = 9.6 
Hz, 1H), 5.58 (d, J = 10 Hz, 1H), 4.15 (s, 2H), 3.82 (s, 3H), 3.22 – 3.11 (m, 4H), 1.45 – 1.39 (m, 
10H).  
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